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Chronic lung diseases (CLDs) are a considerable source of morbidity and mortality and 
are thought to arise from dysregulation of normal wound healing processes.  An aggressive, 
feature of many CLDs is pulmonary fibrosis (PF) and is characterized by excess deposition of 
extracellular matrix (ECM) proteins from myofibroblasts in airways.  However, factors regulating 
myofibroblast biology are incompletely understood.  Proteins in the cadherin family contribute 
epithelial to mesenchymal transition (EMT), a suggested source of myofibroblasts.  Cadherin 
11 (CDH11) contributes to developmental and pathologic processes that parallel those seen in 
PF and EMT.  Utilizing Cdh11 knockout (Cdh11 -/-) mice, the goal of this study was to 
characterize the contribution of CDH11 in the bleomycin model of PF and assess the feasibility 
of treating established PF.  We demonstrate CDH11 in macrophages and airway epithelial cells 
undergoing EMT in lungs of mice given bleomycin and patients with PF.  Endpoints consistent 
with PF including ECM production and myofibroblast formation are reduced in CDH11-targeted 
mice given bleomycin.  Findings suggesting mechanisms of CDH11-dependent fibrosis include 
the regulation of the profibrotic mediator TGF-β in alveolar macrophages and CDH11-mediated 
EMT.  The results of this study propose CDH11 as a novel drug target for PF.  In addition, 
another CLD, chronic obstructive pulmonary disease (COPD), is characterized by airway 
inflammation and destruction.  Adenosine, a nucleoside signaling molecule generated in 
response to cell stress is upregulated in patients with COPD and is suggested to contribute to 
its pathogenesis.  An established model of adenosine-mediated lung injury exhibiting features 
of COPD is the Ada -/- mouse.  Previous studies in our lab suggest features of the Ada -/- 
phenotype may be secondary to adenosine-dependent expression of osteopontin (OPN).  OPN 
is a protein implicated in a variety of human pathology, but its role in COPD has not been 
examined.  To address this, Ada/Opn -/- mice were generated and endpoints consistent with 
COPD were examined in parallel with Ada -/- mice.  Results demonstrate OPN-mediated 
pulmonary neutrophilia and airway destruction in Ada -/- mice.  Furthermore, patients with 
COPD exhibit increased OPN in airways which correlate with clinical airway obstruction.  These 
results suggest OPN represents a novel biomarker or therapeutic target for the management of 
patients with COPD.  The importance of findings in this thesis is highlighted by the fact that no 
pharmacologic interventions have been shown to interfere with disease progression or improve 
survival rates in patients with COPD or PF. 
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Introduction 
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Chapter 1 - Introduction 
 
Chronic lung disease 
Acute lung injuries arise from many well-recognized etiologies.  Examples include 
environmental insults, particularly cigarette smoke, infections, and allergens.  These injuries 
lead to disrupted endothelial and epithelial cell integrity and pulmonary edema.  Under normal 
conditions, there are established response mechanisms for lung tissue repair.  These include 
inflammation, ECM production, deposition, and angiogenesis all encompassing the process of 
normal wound healing.  In the scenario of acute lung injury, tissue undergoes normal healing 
until repair is complete and there is full recovery of function with no long term sequelae.   
For reasons poorly understood, pathways involved in normal wound healing become 
dysregulated or excessive in the context of chronic lung disease.  Hence, these diagnoses, in 
contrast to acute lung injuries, comprise a group of conditions where sustained insults lead to 
permanent changes in lung architecture and its ability to exchange gases.  This leads to 
progressive dyspnea, chronic cough, shortness of breath, and fatigue.  In addition, patients are 
highly sensitive to infections that can lead to acute exacerbations of these symptoms.  
Furthermore, substantial complications occur outside the lung as a consequence of destroyed 
lung parenchyma and disrupted gas exchange.  These include anorexia, cardiac arrhythmias, 
muscle wasting, and pulmonary hypertension, all of which contribute significantly to the overall 
morbidity and mortality of these conditions. 
Examples of chronic lung diseases include asthma, chronic obstructive pulmonary 
disease (COPD), and interstitial lung disease (ILD).  Asthma is characterized by chronic 
inflammation and remodeling of the airways.  Most recognizable features of asthma, however, 
are acute episodes of airway edema, constriction and collapse leading to sudden onset of 
dyspnea.  In addition, asthma may present in a patient at any age.  These features are in 
contrast to COPD and ILD which commonly present in the fourth to sixth decades of life with a 
progressive, insidious onset of dyspnea.   
Although many triggers associated with development of disease are established, the 
details regarding specific factors that drive the chronic nature of these processes remain 
unknown.  Hence, these conditions are irreversible and effective treatments are lacking.  This 
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thesis will focus on novel signaling pathways involved in promoting the chronic features of 
COPD and ILD contributing to the fund of knowledge that will ultimately lead to the 
development of disease-modifying treatments for these devastating conditions.   
 
Chronic obstructive pulmonary disease (COPD) 
Patients with COPD comprise the majority of conditions termed “chronic diseases of the 
lower respiratory tract” which include chronic bronchitis, emphysema, and asthma.  COPD 
affects six percent of the American population, contributes to seven percent of all 
hospitalizations and harbors direct and indirect costs on the order of tens of billions in US 
dollars annually (1).  These conditions are the leading cause of death in America after 
cardiovascular diseases and cancer (2) and the incidence of COPD is projected to increase in 
the next 30 years (3).   
Emphysema, a well-recognized feature of COPD and is most common in people aged 
50 to 65 years who have a history of smoking (4).  However, other less common etiologies of 
emphysema exist including HIV, α1 antitrypsin deficiency, and hypersensitivity pneumonitis.  
Emphysema is defined as destructive, permanent alveolar airspace enlargement in the adult 
lung in contrast to enlarged distal airways secondary to abnormal alveolar development in the 
neonatal lung.  These destructive changes result in progressive loss of patency and elasticity of 
medium and small airways leading to airway obstruction and collapse.     
Most notable histopathologic features of emphysema are the loss of alveolar sacs and 
enlargement of distal air-spaces.  This is accompanied by an inflammatory cell infiltrate (5) 
consisting of neutrophils, CD8+ T-lymphocytes, and macrophages throughout the airways and 
lung parenchyma.  Gene expression and proteomic profiling of samples obtained from patients 
and animal models of emphysema yield select cytokines, growth factors and proteases 
upregulated during this disease.  The roles of these proteins in the contribution to inflammation 
and tissue damage in the acute setting are well-documented.  Despite this knowledge, there is 
a complete lack of therapies that alter disease progression or improve survival rates for 
patients with COPD/emphysema (6).  Signaling pathways involved in the maintenance of the 
chronic inflammation and tissue destruction seen in COPD remain poorly defined.  
Understanding these processes will aid the development of novel treatment strategies and yield 
adequate prognostic biomarkers for better disease management and optimization of treatment 
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options.  Aspects of this thesis will address these gaps in our knowledge with the goal of 
identifying novel pathways that can be targeted for the treatment of COPD.   
 
Pulmonary fibrosis 
The term fibrosis refers to excessive and dysregulated deposition of extracellular matrix 
in an organ.  In many cases, this can be linked to exposure to environmental or iatrogenic 
irritants such as allergens, toxic chemicals, particulate matter, radiation, or chemotherapy.  In 
other cases, particularly in the lung, it may be secondary to systemic inflammatory disorders 
and connective tissue diseases such as sarcoidosis and scleroderma (7-9).  Fibrosis is the 
cardinal feature of a group of chronic lung diseases termed diffuse proliferative lung diseases 
(DPLD) or interstitial lung diseases (ILD).  A particularly deadly form of unknown etiology is 
idiopathic pulmonary fibrosis (IPF).  Less than ten percent of patients show a response to 
available treatments (10) and the condition carries a mean survival time of two to three years at 
time of diagnosis.  Unfortunately, this is attributable to the total absence of disease-modifying 
therapies (11) and a deficiency in understanding the fundamental pathogenic mechanisms of 
the disease.  In addition, many recent studies have impressed that pulmonary fibrosis is a 
compounding pathologic feature in chronic stages of asthma and COPD (12-14).  Hence, while 
sources report pulmonary fibrosis affects roughly 200,000 Americans (15, 16), estimates of 
prevalence and incidence are often understated given its exhibition in this vast array of clinical 
conditions.     
Established histopathologic features of pulmonary fibrosis include variable inflammation 
and the appearance of myofibroblasts in fibrotic foci of the distal airways.  Myofibroblasts 
exhibit contractile properties and a propensity for the synthesis and deposition of extracellular 
matrix proteins (17).  Through these functions, they play a physiologic role in the maintenance 
of structure of the large airways and vessels under normal conditions.  At sites of injury in any 
organ, the appearance of myofibroblasts is a necessary process of normal wound healing (18).  
Naturally, a critical step in repair at sites of injury is the disappearance of myofibroblasts once 
wound healing is complete.  Thus, over-activity and enhanced survival of myofibroblasts is a 
defining feature of pathologic fibrosis.   However, molecular mechanisms promoting the 
formation and survival of myofibroblasts in pathologic situations are not well-understood.  
Detailed investigation into the origin of myofibroblasts and their corresponding processes will 
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be critical in developing therapeutic measures for pulmonary fibrosis.  These concepts and their 
individual contribution to pulmonary fibrosis are explored in this thesis.   
 
Dissertation overview 
The importance of studying the pathogenesis of COPD and ILD is highlighted by the 
fact that no current pharmacologic treatment has been shown to prolong the life of patients with 
these diseases.  In this dissertation, I will introduce adenosine signaling and its role in chronic 
lung disease.  In an effort to understand some of the direct consequences of adenosine 
signaling, I will examine the contribution of osteopontin (OPN) to adenosine dependent lung 
disease.  Results of this investigation displayed that adenosine-dependent upregulations in 
OPN promote recruitment of neutrophils leading to pathologic destruction of alveolar airways.  
This work also demonstrates OPN expression in patients with COPD in association with clinical 
endpoints of disease severity.  These findings highlight OPN and adenosine signaling in the 
continuing pursuit of novel drug targets for the treatment of COPD.  In the second half of this 
dissertation I examined another molecule, cadherin 11 (CDH11), and its specific influence on 
lung myofibroblasts and pulmonary fibrosis.  Findings include CDH11 expression on alveolar 
macrophages and hyperplastic airway epithelial cells playing a role in CDH11-dependent 
expression of the profibrotic mediator TGF-β and epithelial to mesenchymal transition (EMT).  
We also demonstrate improved fibrotic endpoints in mice treated with CDH11-blocking 
antibodies.  These results reveal CDH11 as a novel player in regulating macrophage, airway 
epithelial cell, and myofibroblast biology in the context of pulmonary fibrosis.  Further, we 
introduce CDH11 as a promising drug target for the treatment of pulmonary fibrosis.   
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Chapter 2 
Experimental Procedures 
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Chapter 2 - Experimental procedures  
 
Ada -/- mice.  Ada -/- mice were genotyped and generated as previously described (19, 
20).  Mice homozygous for the Ada null allele were designated Ada-/-, while control mice, 
designated ADA +, were heterozygous for the Ada null allele.  Ada -/- mice were congenic on a 
C57BLk/6J background.  All comparisons were made amongst Ada + littermates.   
Opn knockout (Opn -/-) mice (21) were acquired from Jackson labs where mice were 
previously backcrossed fully onto a C57Bl/6 background.  Ada/Opn double knockout mice 
(Ada/Opn -/-) were generated by breeding Ada -/- mice with Opn -/- mice.  Ada -/- mice were 
identified at birth by screening for ADA enzymatic activity in the blood as described previously 
(22).  For alveolarization experiments, endpoints were collected on postnatal day 10.  For all 
other Ada/Opn -/- studies, Ada -/- mice were maintained on ADA enzyme therapy from postnatal 
day 2 until postnatal day 21 (22).  Endpoints were collected on postnatal day 37.   
CD44 neutralization experiments.  Ada -/- mice were on a 129/Sv C57BL/6 mixed 
background.  These mice were maintained on ADA enzyme therapy from postnatal 2 until 
postnatal 25.  Beginning at postnatal day 33, mice were given intraperitoneal (IP) injections of 
CD44 blocking antibody (Ab) (100 µg in 100 µl, Rat monoclonal KM114, BD Biosciences) or the 
manufacturer’s isotype control Ab every other day until postnatal day 40.  Endpoints were 
collected on postnatal day 41.   
Bleomycin installation.  Eight to twelve week old mice were anesthetized with 250 
mg/kg IP avertin and received 50 µl intratracheal sterile saline or bleomycin (Blenoxane, Teva 
Pharmaceuticals) at 3.5U/kg diluted in sterile saline.  All endpoints were examined at day 21 
after exposure.   
CDH11 neutralization experiments.  Delivery schedule for CDH11-blocking Abs was 
based on a previous report of systemic CDH11 neutralization experiments (23).  For our 
purposes, mice were given IT bleomycin as above and treated with a loading dose of 500 µg 
Ab (clone 23C6, clone 13C2, or isotype control Ab (mouse monoclonal, MOPC 31C clone, 
Sigma)) resuspended in 100 µL sterile, endotoxin-free PBS at 10 days after bleomycin 
exposure.  Mice were subsequently administered 100 µg Ab in 100 µL PBS every other day 
until day 20.  All endpoints were collected on day 21 (Figure 2.1).   
Mice.  Eight to twelve week old C57BLk/6J female mice used for peritoneal lavage and 
CDH11 neutralization experiments were purchased from Harlan.  Cadherin 11-null (Cdh11 -/-) 
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mice on the C129 background were previously backcrossed onto the C57/B6 background (23, 
24).  These studies were reviewed and approved by the University of Texas Health Science  
 
Figure 2.1 - Bleomycin model and CDH11 treatment strategy 
The intratracheal bleomycin model of pulmonary fibrosis can be divided into two stages: 
“Inflammation” and “Fibrosis”.  The upregulation of profibrotic mediators and appearance of 
ECM and myofibroblasts begins at day 7 after bleomycin exposure.  The CDH11 treatment was 
designed such that mice would receive CDH11 antibody (blue arrows) after the onset of 
fibrosis.  
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Center at the Houston Animal Welfare Committee in Houston, Texas, USA.  All mice were 
housed in ventilated cages equipped with microisolator lids and maintained under strict 
containment protocols. No evidence of bacterial, parasitic, or fungal infection was found, and 
serologies on cage littermates were negative for 12 of the most common murine viruses. 
 
Bronchoalveolar lavage (BAL), airway inflammatory cell counts, and differentials.  Mice 
were anesthetized with avertin, lungs were lavaged 4 times with 0.3 to 0.4 mL PBS and 1.0 mL 
of pooled lavage fluid was recovered.  Total BAL inflammatory cells were counted with a 
hemocytometer.  BAL samples were spun at 4 °C and cell pellets were spun on microscope 
slides and stained with Diff-Quick (Dade Behring) for cellular differential determination.  BAL 
cell pellets and supernatants were aliquoted and saved for protein quantification (Sircol 
collagen assay, Biocolor Assays) (Mouse TGF-β, CXCL-1, TIMP-1 Quantikine ELISAs, R&D 
systems) performed according to manufacturer’s instructions.   
 
Histology, air-space size, and fibrosis assessment.  Mouse lungs were inflated at 25 cm 
H2O pressure and fixed with 10% phosphate buffered formalin.  Fixed lungs were dehydrated 
through ethanol gradient, embedded in paraffin, and 5 µm sections were cut.  Lung sections 
were rehydrated through graded ethanol to water and stained with H&E (Thermo Electron 
Corp) or Masson’s trichrome (EM Science) according to manufacturer’s instructions.  Eight 
unique, representative digital images were taken from each H&E stained mouse lung section at 
20X magnification and alveolar airway size was assessed by mean chord length measurement.  
A line grid spaced at 10.5 µm intervals was overlaid on each image using image analysis 
software (Image Pro Plus 4.0, Media Cybernetics).  The resultant lines were measured and 
averaged to give mean chord length of the alveolar airways.  Fibrosis was quantified using the 
Ashcroft scoring method (25) on 20 images per H&E-stained mouse lung.  Analyses were 
performed blinded with regard to animal genotype and/or treatment.   
Immunostaining.  Sections were rehydrated, endogenous peroxidases were quenched 
with 1% hydrogen peroxide, antigen retrieval was performed (Dako), and endogenous avidin 
and biotin was blocked with the Biotin-Blocking System (Dako).  Slides were incubated with 
primary Abs for α SMA (1:500 dilution, 4º overnight, mouse monoclonal, Sigma-Aldrich), MMP-
9 (1:50 dilution, 1 hr room temperature, goat monoclonal, R&D Systems), neutrophil marker 
(1:200 dilution, overnight 4ºC, rat anti-mouse allotypic neutrophil marker, AbD Serotec), CD44 
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(1µg/ml, 1 hr room temperature, rabbit polyclonal, Abcam), CDH11 (10 µg/ml, overnight 4°C, 
mouse monoclonal, invitrogen) human OPN (1:250 dilution, 1 hr room temperature, rabbit 
polyclonal, Calbiochem).  For α SMA staining, sections were processed with the Mouse on 
Mouse kit (VectorLabs).  All sections were incubated with ABC Elite Streptavidin reagents and 
appropriate secondary Abs, developed with 3,3'-diaminobenzidine (Sigma-Aldrich) and 
counterstained with methyl green.  Quantification of distal airway neutrophils and MMP-9 
positive cells was performed on 20 fields per mouse lung section at 20X magnification.  
Positive staining cells were identified and counted using software analysis (Image Pro Plus 4.0, 
Media Cybernetics).     
Immunofluorescence.  Sections were rehydrated and fixed with acetone and methanol.  
Endogenous fluorescence was quenched with NaBH4.  Slides were incubated with primary Ab 
to fibronectin (1:400 dilution, 1 hr room temperature, rabbit polyclonal, Sigma-Aldrich) followed 
by secondary Ab (1:1000 dilution, 1 hr room temperature, donkey anti-rabbit IgG Alexa fluor 
555-red, Invitrogen).  Sections were covered with Vectashield anti-fade medium with DAPI 
(VectorLabs).  BAL cell pellets were cytospun onto microscope slides, allowed to air-dry, and 
fixed in acetone and methanol.  Slides were incubated with primary Abs for mouse CDH11 (5 
µg/ml, 1 hr room temperature, clone 23C6 mouse monoclonal), mouse CDH11 (1:100 dilution, 
1 hr room temperature, Invitrogen, mouse monoclonal), N cadherin (1:100 dilution, 1 hr room 
temperature, Invitrogen, mouse monoclonal), and human β catenin (1:100 dilution, 1 hr room 
temperature, Invitrogen, rabbit polyclonal) followed by secondary Abs (1:1000 dilution, 1 hr 
room temperature, donkey anti-mouse IgG Cy3, Jackson Immunoresearch Laboratories) 
(1:1000, 1 hr room temperature, goat anti-rabbit Alexa flour 488, Invitrogen), and covered with 
Prolong Gold anti-fade medium with DAPI (Invitrogen).  Confocal images on BAL cytospins 
were obtained using a TCS SP5 confocal laser microscope (Leica).   
 
Western blot detection of CDH11.  Protein lysates were prepared from homogenization 
of frozen tissue in cold lysis buffer (150 mM NaCl, 50 mM Tris, pH 7.4, 1% Triton X-100) 
containing protease inhibitor cocktail (Roche) in a Polytron homogenizer.  Protein 
concentrations from BAL cell pellets, mouse and human lungs were determined by Bradford 
assay (Bio-Rad).  Equal protein quantities were diluted 1:1 by volume with Laemmli sample 
buffer (BioRad) and incubated at 95 °C for 5 minutes.  Samples were then added to 10% Tris-
HCl SDS Ready-Gels (Bio-Rad), separated by electrophoresis, and transferred onto PVDF 
membranes (Millipore).  Membranes were blocked with 5% dehydrated milk and 0.02% sodium 
azide in TBS/T (1 hour, room temperature), incubated with primary Ab (CDH11, mouse 
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monoclonal, 1:500, Invitrogen), (α-tubulin, mouse monoclonal, 1:5000, Sigma-Aldrich) diluted in 
0.5% BSA and 0.02% sodium azide in TBS/T at 4 °C overnight, incubated with secondary Abs 
conjugated to HRP (1:5000, eBiosciences), and detected with ECL reagents (Amersham).    
Analysis of whole lung mRNA.  Mice were anesthetized with avertin and lungs were 
quickly removed and frozen in liquid nitrogen.  RNA was isolated from frozen lung tissue using 
TRIzol reagent (Invitrogen) according to the manufacturer’s instructions.  RNA was then DNAse 
(Invitrogen) treated and used for quantitative real time RT-PCR analysis.  Primer sequences for 
uPA: forward 5’ CCTACAATGCCCACAGACCT 3’ and reverse 5’ 
GCTGCTCCACCTCAAACTTC 3’.  For CD44: forward 5’ AGAGATCGAGACTCATCCAA 3’ and 
reverse 5’ CCCAATCTTCATGTCCACAC 3’.  Other primers, probes, and procedures for real 
time RT-PCR were as described previously (19, 26).  Sample reactions were performed on a 
SmartCycler System (Cepheid).  Specific transcript levels for mouse OPN were determined 
through comparison to a standard curve generated from the PCR amplification of template 
dilutions or measured in parallel with β-actin and presented as mean % β-actin.  Transcripts for 
human OPN, CXCL1, CCL7, and α1 procollagen were measured in parallel with 18S rRNA and 
values are presented as mean %18S rRNA.  Transcripts for mouse and human CDH11 
obtained with corresponding Taqman probes (Applied Biosystems) and measured in parallel 
with PPIA and values are presented as mean normalized transcript levels using the 
comparative Ct method (2∆∆Ct) (27).  Remaining transcript levels were calculated using SYBR 
Green method in SmartCycler Software (version 4.0, Cepheid) and normalized to transcript 
levels of 18S rRNA in the corresponding sample and are presented as mean normalized 
transcript levels using the comparative Ct method (2∆∆Ct).   
Analysis of A549 cells.  A549 cells (ATCC) were seeded in 96 well plates and grown 
overnight in DMEM containing 10% FBS and 1% antibiotics.  For siRNA knockdown of Cdh11, 
cells were washed with antibiotic free media and subsequently incubated with Optimem 
(Invitrogen) with Lipofectamine RNAiMax (Invitrogen) and either non-targeting siRNA or human 
Cdh11 siRNA (antisense sequence: 5’-UUUGAAUGGAGUCAUAAGGUU) (Dharmacon RNAi 
technologies, Thermo) for 48 hours.  Cells were then trypsinized and reseeded in antibiotic free 
medium.  Six hours later, cells were serum-starved overnight in DMEM containing 0.1% BSA.  
Cells were then stimulated with or without TGF-β at 10 ng/ml in DMEM + 0.1% BSA for 24 
hours.  RNA was isolated using Cell to Ct reagents (Ambion) according to manufacturer’s 
instructions.  Transcripts for CDH11, COL1A1, N cadherin (Cdh2), and E cadherin (Cdh1) were 
obtained with corresponding Taqman probes (Applied Biosystems) and presented as mean fold 
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change versus control.  Imaging of A549 cells was performed with a BX60 inverted phase 
contrast microscope (Olympus) for determination of cellular morphology.   
In vivo neutrophil migration.  Wild type C57/B6 female mice were anesthetized with 
isofluorane and pretreated with intraperitoneal (IP) injection of 300 µL isotype control Ab, β3 
integrin neutralizing Ab (Biolegend), or CD44 neutralizing Ab (BD Pharmingen).  After 15 
minutes, neutrophil recruitment in vivo was assessed with 100 µL intraperitoneal (IP) 
administration of PBS alone or containing BSA, CXCL-1 (R&D Systems), OPN (R&D Systems), 
or BAL fluid isolated from one of four mouse genotypes at postnatal day 37 as described 
above.  After 3.5-4.5 hours, mice were killed and 2 mL of PBS was used to lavage the 
peritoneal cavity to recover peritoneal inflammatory cells.  Cellular differentials were 
determined on cell suspensions cytospun on microscope slides and stained with Diff-Quick 
(Dade-Behring).   
Human lung samples.  Deidentified human lung tissue samples were obtained from the 
Lung Tissue Research Consortium (Bethesda, MD, USA).  Patients were classified as at risk 
COPD (Gold Stage 0), severe COPD (Gold Stage 4), Mild IPF, and severe IPF according to 
spirometry, pathological specimen and high resolution CT scan.  Mild/at risk COPD/IPF 
patients were used as controls in comparison to corresponding severe COPD/IPF patients.  
Quantification of OPN positive staining cells in each group was performed on 12 images of the 
alveolar airways per human lung section at 10X magnification.  Positive staining cells were 
identified and counted using software analysis (Image Pro Plus 4.0, Media Cybernetics). 
Whole mount immunohistochemistry for CD31 on tracheas.  Methods for tracheal whole 
mount immunohistochemistry were as previously described (28).  Briefly, mice were 
anesthetized, tracheas were excised, surrounding soft tissue was removed, and tracheas were 
pinned flat onto silicone polymer.  Tracheas were subsequently fixed with zync fixative (BD 
Pharmingen) for 72 hours at 4 ºC.  Following fixation, tracheas were washed, permeabilized 
with 1% Triton X-100, and endogenous peroxidases were quenched with 0.06% hydrogen 
peroxide.  Immunohistochemistry for CD31 (1:250 dilution, room temperature overnight, rat 
anti-mouse, BD Pharmingen) was performed according to the manufacturer's guidelines with 
anti-rat Ig horseradish peroxidase detection kit (BD Pharmingen).  Tracheas were dehydrated 
and mounted onto microscope slides with Permount (Fisher Scientific).  Number of CD31 
positive vessels traversing tracheal cartilage rings was determined to estimate angiogenesis 
present in the lung (29).  This value was determined with placement of a line of known length 
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parallel to the long axis of a cartilage ring and counting the number of vessels intersecting the 
line. 
Mucus quantitation.  Mouse lung sections collected and prepared as above were 
stained with Periodic Acid-Schiff and counterstained with Alcian Blue.  Quantification of mucus 
production was obtained by mucus index scoring (Image Pro Plus 4.0, Media Cybernetics) (30) 
determined by dividing ((area of PAS staining) x (mean PAS intensity)) by the total airway 
epithelium area.   
Peripheral blood differentials.  Mice were anesthetized with avertin and peripheral blood 
was collected into tubes containing 0.5M EDTA from subaxillary arteries, bilaterally.  Red blood 
cells were removed through dextran sedimentation and hypotonic lysis (dH2O followed by 0.6 M 
KCl).  Absolute leukocyte count (per mL) was determined by hemocytometer.  Isolated 
leukocytes were cytospun onto microscope slides, stained with Diff-Quick, and differentials 
were determined by light microscopy.   
Statistics.  Values are expressed as mean ± SEM.  As appropriate, groups were 
compared by analysis of variance (ANOVA) and follow-up comparisons between groups were 
conducted using 2-tailed Student’s t test.  The correlation of OPN immunostaining and clinical 
endpoints was determined by Pearson correlation.  The P value of ≤ 0.05 was considered to be 
significant. 
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Chapter 3 
Osteopontin and adenosine 
contribute to features COPD 
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Chapter 3 - Introduction 
COPD 
COPD is a chronic condition affecting the lung characterized by progressive dyspnea 
secondary to collapse, obstruction, and loss of elastic recoil of large airways, and destruction of 
smaller alveolar air-spaces (4).  Many inciting factors have been associated with the 
development of COPD including cigarette smoke, infections, and environmental 
agents/allergens.  These various insults converge on the induction of cell stress and injury.  
Adenosine is a nucleoside signaling molecule generated in excess at these sites of tissue 
damage.  Not surprisingly, adenosine levels are elevated in bronchoalveolar lavage (BAL) fluid 
from patients with COPD (31). Furthermore, bronchoconstriction, a pathologic feature of 
COPD, is elicited by exogenous adenosine administration in patients with obstructive airway 
disease, but not in normal patients (32).  This suggests altered adenosine signaling exists in 
patients with COPD.  Additionally, adenosine signaling has been shown to influence the 
processes of inflammation, angiogenesis, and fibrosis (33-35).  These are primary 
histopathologic features of COPD; thus adenosine signaling represents an important area of 
study for the pathogenesis of this disease.   
Adenosine 
Adenosine is a nucleoside signaling molecule produced at sites of tissue stress or injury 
(Figure 3.1).  Under normal conditions, circulating concentrations of adenosine vary from 40-
600 nM (36).  In these scenarios, the majority of adenosine is generated as a result of 
increased intracellular generation from ATP leading to passive transfer through equilibrative 
transporter proteins (37).  In contrast, in the setting of acute cellular stress, the predominant 
origin of adenosine arises from the dephosphorylation of released adenine nucleotides (38, 39).  
ATP and ADP can escape cells through transporters present on the plasma membrane (40-45), 
via fusion of vesicles, or from degranulating inflammatory cells.  These nucleotides are 
dephosphorylated to AMP by the ectonucleoside triphosphate diphosphohydrolase CD39 (46).  
AMP is subsequently dephosphorylated to adenosine by the ecto-5’-nucleotidase CD73 (47).  
These enzymes are upregulated following injury leading to enhanced adenosine generation 
(38, 39).   
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Adenosine signaling has diverse effects on human physiology and pathophysiology and 
is centered on a wide tissue distribution of adenosine receptors and the variety of signaling 
pathways to which they are coupled.  Four unique, seven membrane spanning, G protein- 
 
 
Figure 3.1 - Generation of extracellular adenosine 
Cellular stress and inflammatory cell infiltration yield the liberation of ATP into the extracellular 
space.  Adenosine is generated via the actions of two extracellular enzymes, CD39 and CD73, 
present on the cell surface.  Adenosine is free to interact with one of four cell surface receptors 
resulting in changes in many intracellular signaling pathways.
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coupled adenosine receptors have been described (48): A1 receptor (A1R), A2AR, A2BR, and 
A3R.  Classically, A1 and A3 are coupled to Gαi-proteins leading to the decreased production of 
the second messenger cyclic AMP through the inhibition of adenylate cyclase (49, 50).  
Conversely, A2A and A2B are frequently coupled to Gαs-proteins resulting in increased cyclic 
AMP levels via stimulation of adenylate cyclase (49, 50).  Additionally, other intracellular 
pathways involved include Gq protein-mediated stimulation of phospholipase C and various 
kinase pathways including MAP kinase, protein kinase C, and phosphoinositide 3 kinase.   
Under physiologic conditions, the engagement of adenosine receptors promotes the 
regulation of a variety of homeostatic functions including heart rate (51, 52) and body 
temperature (53).  Additionally, adenosine signaling mediates a variety of adaptive functions.  
These include response to pain (54), adaptation to hypoxia (55), and the regulation of blood 
flow through vasoconstriction (56), vasodilation (57), and platelet aggregation (54).   
In addition to homeostatic functions, adenosine has multiple effects on the regulation of 
immune responses in the setting of pathology.  Acute tissue injury such as sepsis or ischemia 
yields adenosine concentrations reaching 10 µM (58).  Increased adenosine concentrations in 
the setting of acute pathology generally access tissue protective and anti-inflammatory 
pathways through the high affinity A1 and A2A receptors.  For example, activation of the A1 and 
A2A receptors attenuates inflammation in models of ischemia-reperfusion and LPS-induced 
injury in multiple organs (59-65).   
Furthermore, concentrations in excess of 100 µM are reported in chronic conditions 
such as rheumatoid arthritis (66), asthma and COPD (31).  Hence, chronic adenosine 
elevations in persistent inflammatory conditions, particularly chronic lung diseases, have 
proinflammatory and tissue destructive consequences through engagement of the low affinity 
A2B and A3 receptors.  For example, features of asthma, such as mast cell degranulation (67-
69) and eosinophil trafficking (22), are promoted through engagement of the A3 receptor.  
Suggested mediators of chronic lung disease are elicited from bronchial smooth muscle cells 
(22), fibroblasts, and macrophages (70, 71) through engagement of the A2B receptor.  
Furthermore, activation of the A2B receptor on fibroblasts induces differentiation into 
myofibroblasts (72) suggesting a mechanism of adenosine-dependent airway remodeling and 
fibrosis.  Despite these findings, the detailed molecular mechanisms of adenosine-dependent 
lung injury remain unknown.  To address this, in vivo studies conducted in a mouse model are 
a necessary step toward a full understanding of the role of adenosine in lung disease. 
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Ada -/- mice 
The Ada -/- mouse is a well-established model designed to investigate the sequelae of 
increased concentrations of adenosine in vivo.  Degradation of extracellular adenosine and 
deoxyadenosine is accomplished through the activity of the enzyme ADA (Figure 3.1).  Thus, 
genetic ablation of Ada results in considerable systemic elevations of these substrates which 
directly promote multi-organ pathology (30).  For example, deoxyadenosine accumulation in 
the spleen and thymus leads to a severe combined immunodeficiency displayed in this model.  
Most notably, adenosine concentrations in the lungs of Ada -/- mice correlate with measured 
levels in lungs of patients with asthma and COPD (31).  In parallel with adenosine 
accumulations, Ada -/- mice exhibit pulmonary inflammation and histopathologic changes in 
lung architecture that resemble findings in human lung disease (30).  Namely, features 
consistent with asthma include eosinophilia, mucus metaplasia, and mast cell degranulation.  
Neutrophilia, activation of alveolar macrophages, and distal air-space enlargement are features 
consistent with COPD.   
Ada -/- mouse
 
lungs display upregulations of cytokines and mediators commonly 
elevated in association with asthma and COPD.  For example, serum IgE and TH2 cytokines 
are increased in Ada -/- mice (30) and patients with asthma.  Similarly, Ada -/- mice and humans 
with COPD display increases in chemokines and cytokines that recruit macrophages and 
neutrophils to the lungs (71, 73).  In addition, both exhibit upregulations in mediators of air-
space enlargement such as MMPs and cathepsins (71, 73).  Grossly, these mice will display 
labored breathing and dehydration.  Thus, findings that adenosine concentrations exceeding 
the normal physiologic range are associated with pathology suggest that adenosine directly 
promotes these disease processes. 
ADA enzyme replacement therapy utilized to reduce systemic adenosine levels support 
the suggestion that features of the lung phenotype are a direct consequence of adenosine 
signaling.  Administration of ADA covalently linked to polyethylene glycol (PEG-ADA) to Ada -/- 
mice prevents and reverses every aspect of the pulmonary phenotype and maintains the health 
of the animal indefinitely (30).  Other mouse models of lung injury, including transgenic IL-4 
and IL-13 mice exhibit elevated adenosine levels concurrent with active lung disease 
consistent with emphysema and fibrosis.  Furthermore, these features were also abolished by 
lowering adenosine levels with PEG-ADA in these models.  These findings reveal an obvious 
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correlation between adenosine concentrations, lung pathology, and its contribution to overall 
morbidity.   
Additionally, the use of PEG-ADA permits the study of pulmonary fibrosis in Ada -/- mice 
(26).  Without PEG-ADA these animals die at three weeks of age from presumed respiratory 
complications before the onset of fibrosis.  By administering a tapered regiment of PEG-ADA, 
adenosine levels will elevate slowly, life spans of mice are prolonged, and pulmonary fibrosis 
will develop.  Lung sections from Ada -/- mice in this scenario exhibit increased alveolar and 
peribronchial staining for collagen and myofibroblasts.  In parallel, measurable elevations in 
soluble collagen are present in BAL samples.  Finally, Ada -/- mouse lungs also have 
upregulations in established profibrotic mediators.  These include TGF-β, IL-1β, IL-13, MMP-2, 
osteopontin (OPN), and PAI-1.  Concurrent with histological findings, these results display that 
adenosine signaling accesses profibrotic pathways contributing to the overall chronic 
pulmonary disease phenotype these mice display.   
As with features in this model consistent with COPD and asthma, fibrotic endpoints can 
be prevented and reversed by maintaining low adenosine concentrations with PEG-ADA (26).  
Additionally, elevated adenosine levels are present in the standard model of bleomycin-
induced fibrosis and all features of this model are prevented and reversed by diminishing 
adenosine levels with PEG-ADA.  Overall, adenosine concentrations are clearly associated 
with many features of chronic lung disease and these findings underscore the necessity of 
understanding the role of adenosine in promoting the chronic nature of these pathologic 
processes.   
Adenosine receptor signaling in the Ada -/- model 
Genetic and pharmacologic targeting of adenosine receptors in the Ada -/- model 
suggest that adenosine signaling may directly influence changes that lead to the development 
of chronic lung disease features.  Increased expression of the A3R is localized to key effector 
cells mediating features of asthma including eosinophils, mast cells, and bronchial epithelial 
cells (22, 69).  Genetic and pharmacologic targeting of the A3R in Ada -/- mice displayed 
diminished mast cell degranulation, eosinophil trafficking, and mucus production.  Additionally, 
levels of TH2 cytokines commonly elevated in allergic airway disease were reduced in these 
studies.  These findings highlight the pathologic role of A3R signaling.   
Similar to roles in acute tissue injury in other models, other work in the Ada -/- model 
shows a protective role of adenosine signaling through the A1 and A2A receptors.  Specifically, 
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genetic knockout of these receptors results in enhanced pulmonary inflammation, mucus 
production, and pathologic air-space enlargement in association with increases in 
proinflammatory cytokines and mediators of air-space enlargement (19, 28).  In contrast, 
similar to the pathologic role of the A3R, most recent work in the Ada -/- model demonstrates 
that these features are promoted by A2BR signaling.  Selective antagonism of the A2BR in Ada -/- 
mice prevented features of emphysema including influx and activation of macrophages and 
neutrophils, air-space enlargement, and upregulations in proinflammatory cytokines and 
mediators of air-space enlargement.  Additionally, features of pulmonary fibrosis are also 
regulated by A2BR signaling.  Namely, treatment with the selective A2BR antagonist yields a 
reduction in distal airway collagen and α SMA in addition to a reduction in the profibrotic 
mediators TGF-β, PAI-1, and OPN (71).   
In summary, these results suggest that the A2AR and A1R promote tissue protection and 
the A2BR and A3R are playing a pathologic role (Figure 3.2).  These results displayed in Ada -/- 
mice support the suggested benefit of selective adenosine receptor agonists and antagonists in 
the treatment of chronic lung diseases.  This highlights the importance of understanding the 
consequences of adenosine receptor signaling in humans and other animal models of lung 
disease. 
Ada -/- mice, the A2B receptor, and OPN 
Despite the clear association of adenosine levels and lung pathology, the mechanisms 
of adenosine-dependent lung injury are incompletely defined.  To identify pivotal mediators in 
the Ada -/- model, gene array profiling was performed in comparison to Ada-competent (Ada +) 
littermates (73).  Results of this study demonstrated that OPN was the most highly upregulated 
gene and that its expression was lowered to baseline by administration of PEG-ADA.  
Subsequent studies in Ada -/- mice display adenosine-dependent OPN expression in alveolar 
macrophages during active disease (71).  In this study, systemic pharmacologic neutralization 
of the A2BR prevented all aspects of the pulmonary phenotype in Ada -/- mice and concurrently 
reduced expression of OPN in alveolar macrophages.  Follow-up studies confirmed increased 
expression of OPN in lungs of Ada -/- mice (Figure 3.3A, B), displayed elevated levels of OPN in 
BAL fluid (Figure 3.3C), and confirmed A2BR-dependent expression of OPN in alveolar 
macrophages (Figure 3.3D, E).  These findings suggest that adenosine signaling through the 
A2BR regulates the expression of OPN on alveolar macrophages.   As discussed in detail later 
in this chapter, many recent studies in mouse models and humans have showcased OPN as a 
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major mediator of lung injury.  Therefore, many of the pathologic features of A2BR signaling 
displayed in the Ada -/- model may be a consequence of A2BR-dependent upregulations in OPN.   
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Figure 3.2 - Adenosine receptor activities in the lungs of Ada -/- mice 
Genetic and pharmacologic studies in the Ada -/- model suggest that adenosine receptor 
signaling influences both tissue-protective and tissue-destructive pathways in the lungs. 
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Figure 3.3 - A2BR-dependent OPN expression in alveolar macrophages of Ada -/- mice 
Quantitative RT-PCR measuring OPN transcripts in RNA extracts from (A) whole lung and (B) 
BAL cell pellets.  For (A), data are presented as mean transcripts per picogram RNA + SEM.  n 
= 4 mice.  For (B), data are presented as mean transcripts as a percent of β-actin + SEM.  n = 
5 mice.  *P < 0.05 versus Ada + mice.  (C) Western blot of secreted OPN in BAL fluid.  (Left) 
MWM, (Right) recombinant OPN showing full length (65 kDa) and cleaved (30 kDa) protein.  
(D) Immunofluorescence detection of OPN (green) in primary alveolar macrophages isolated 
from BAL fluid of Ada + and Ada -/- mice.  Compartmentalized localization of OPN (arrow).  
Scale bars: 50 µm.  (E) Primary alveolar macrophages isolated from Ada + or A2BR -/- mouse 
lungs incubated with the non-specific adenosine receptor agonist, NECA and/or the selective 
A2BR antagonist, MRS 1706.  Data are presented as normalized mean fold change + SEM.  *P 
< 0.05 versus media A2BR +/+ macrophages; # P < 0.05 versus NECA A2BR +/+ macrophages.  
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Experiments performed by Janci C. Lindsay.  
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Osteopontin 
The manner in which OPN entered the scientific literature conveys its diverse, widely-
expressed, multifunctional nature. Its primary structure was originally discovered in the late 
1970s as a protein secreted from malignant tumors, but was twice independently discovered as 
a protein isolated from bone extracellular matrix (74) and activated T cells (75).  OPN functions 
in a variety of physiologic and pathologic processes including bone remodeling, cancer, 
immunity and inflammation.  These processes can be influenced through changes in gene 
expression, alternate splicing, and post-translational modifications (Figure 3.4) such as 
glycosylation, phosphorylation, and proteolytic cleavage by thrombin and MMPs (76, 77).   
OPN is a mediator of cell adhesion and migration through its interactions with various 
integrin receptors.  The primary protein sequence of OPN (Figure 3.4) includes an Arg-Gly-Asp 
(RGD) domain common to many ECM proteins which mediates adhesion to various integrin 
receptors.  Adjacent to the RGD domain is a separate SVVYGLR sequence (Figure 3.4) that 
mediates cellular adhesion via many integrins including α9β1 and α4β1 (78, 79).  Of these OPN-
integrin interactions, binding with integrin αvβ3 has been shown to promote cellular migration.  
OPN-αvβ3-dependent cellular migration has been described in smooth muscle cells (80), 
endothelial cells (81), alveolar epithelial cells (82), tumor cells (83), and macrophages (84).  
Additionally, OPN, through non-RGD and SVVYGLR-containing domains, interacts with 
variants of the hyaluronic acid receptor CD44.  These interactions promote cell migration in 
various cell types including tumor cells (83, 85), lymphocytes, fibroblasts (75, 82, 86) and 
macrophages (87).  Thus, αvβ3 integrin and CD44 are considered the putative OPN receptors.   
Osteopontin in cancer 
In addition to promoting cellular migration of tumor cells through interactions with CD44 
and αvβ3, OPN interactions with these receptors have been shown to promote malignancy and 
metastasis.  Several studies in multiple forms of cancer cite OPN-αvβ3-dependent angiogenesis 
as a factor in tumor growth and metastatic potential (76, 81).  Furthermore, the presence and 
activation of matrix degrading proteases facilitates the migration and metastasis of tumor cells. 
Studies in prostate cancer and melanoma have demonstrated OPN promotes regulation and 
activation of multiple proteases through interactions with CD44 and αvβ3 (88-90).  Thus, OPN 
directly influences three independent mechanisms facilitating malignancy and metastasis.  
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Importantly, dysregulation of these three processes, cell migration, extracellular matrix 
turnover, and angiogenesis, are major mechanisms in the pathogenesis of chronic lung  
 
 
Figure 3.4 - Primary sequence and post-translational modification sites of osteopontin 
Schematic representation of the protein sequence of human OPN depicting RGD, SVVYGLR 
functional domains, and post-translational modification sites (proteolytic cleavage, glycosylation 
and phosphorylation).
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disease.  Through these studies in cancer, it follows that OPN has the potential to be an 
important mediator of chronic lung diseases.  
  OPN as a modulator of immunity in human disease 
OPN interactions with the two putative OPN receptors modify immune responses that 
are pivotal in the pathogenesis of human disease outside the cancer field.  Classically, OPN is 
a known regulator of TH1 cytokine profiles.  Specifically, OPN binding αvβ3 yields IL-12 
expression from macrophages and, through interaction with CD44 inhibits the production of IL-
10 (84).  OPN-αvβ3 interaction also upregulates IFN-γ expression in natural killer T-Cells (91).  
These features are central in the role of OPN in granulomatous lung diseases including 
tuberculosis, silicosis, and sarcoidosis (92-94).  In addition, OPN-dependent TH1 linked 
responses are demonstrated in a variety of in vivo models.  Namely, Opn -/- mice display 
diminished immunity to viruses (84) and are protected from experimental autoimmune 
encephalomyelitis (95) and keratitis (84).  In contrast, it was recently reported that OPN also 
influences TH2 cytokine response patterns (96).  This study demonstrated that OPN, through 
regulation of TH2 cytokine expression from dendritic cells, has an important role in allergic 
airway disease.  These results demonstrate the wide capacity of OPN to affect conditions to 
promote human disease, including lung disease.  
OPN in lung disease 
The aforementioned studies facilitated the investigation of OPN in chronic forms of lung 
pathology.  Microarray studies in patients with IPF show upregulation of OPN when compared 
to normal patients (82).  Furthermore, OPN -/- mice are protected from pulmonary fibrosis in the 
standard model of intratracheal bleomycin installation (97, 98).  Despite the fact that OPN has 
been extensively associated with the development of pulmonary fibrosis in patients and animal 
models, the mechanisms of OPN-driven fibrosis have not been elucidated.    
The role of OPN in lung pathology has expanded recently to include other diseases 
such as acute respiratory distress syndrome (99) and bronchiolitis obliterans (100).  These 
conditions display inflammation and protease dependent destruction and remodeling of the 
alveolar air-spaces.  These pathologic features exist in a more chronic form known as 
emphysema and the role of OPN in emphysema has received limited attention.  However, one 
study demonstrated elevated OPN expression in alveolar macrophages of smokers and 
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correlated OPN expression levels with the degree of airway obstruction in these patients (101).  
Other studies in patients and animal models of emphysema (102-105), including the Ada -/- 
model (71), link the activity of certain MMPs with the development of air-space destruction.  As 
mentioned previously, in vitro studies of tumor cells demonstrate OPN-dependent activation 
and expression of MMPs (88, 89), which suggest a potential mechanism of OPN-mediated air-
space enlargement. 
Associations of OPN and these chronic lung diseases are consistent with studies in 
cancer showing OPN can influence cell migration, angiogenesis, and matrix degrading 
proteases.  Furthermore, these studies are supported by findings in the Ada -/- model that 
display upregulations in OPN during active pulmonary disease consisting of inflammation, air-
space enlargement, and fibrosis.  Taken together, these studies led to the development of the 
hypothesis that OPN contributes to pulmonary phenotypic features in Ada -/- mice.   
To investigate this, Ada/Opn -/- mice were generated and their pulmonary phenotype 
was assessed in parallel with Ada -/- mice.  Results indicate that the genetic removal of Opn in 
Ada -/- mice leads to reduced histopathologic and biochemical features of pulmonary 
inflammation and emphysema. In addition, results demonstrate novel OPN interactions on 
neutrophils offering a mechanism for increased protease concentrations within alveolar air-
spaces.  Furthermore, these studies demonstrate that OPN is not required for the development 
of pulmonary fibrosis in this model but influences select mediators and features of the 
phenotype.  Finally, OPN expression is increased in distal air-spaces of lung samples obtained 
from patients with COPD. Thus, OPN may represent a novel drug target and/or clinical 
indicator of COPD. 
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Chapter 3 - Results 
Histopathology in Ada/Opn -/- mice   
OPN is suggested to contribute to pathology in animal models (97, 98, 106) and 
humans (82) with chronic lung disease.  To determine the contribution of OPN to the Ada -/- 
pulmonary phenotype, Ada/Opn -/- mice were generated and compared in parallel with Ada -/- 
mice.  Ada -/- mice were treated with PEG-ADA from birth until postnatal day 21 to prevent 
defects in lung development.  All pulmonary endpoints were assessed 16 days after cessation 
of PEG-ADA treatment at postnatal day 37, a stage when adenosine levels are elevated in 
association with severe pulmonary inflammation and damage (71).  Examination of H&E 
stained lung sections demonstrated no discernable difference in pulmonary histology between 
Ada + and Opn -/- mice (Figure 3.5).  Ada -/- mice exhibited characteristic increases in pulmonary 
inflammation and destruction of the alveolar air-spaces.  In contrast, Ada/Opn -/- mice showed 
reduced pulmonary inflammation and distal air-space destruction.  Overall, these findings 
suggest that OPN contributes to histopathologic features of Ada -/- mice.   
Quantification of pulmonary inflammation in Ada/Opn -/- mice   
The characteristic inflammatory cell infiltrate in lungs of Ada -/- mice includes 
macrophages, neutrophils and lymphocytes (30, 71).  To confirm histologic findings of reduced 
pulmonary inflammation in Ada/Opn -/- mice, inflammatory cells were quantified by counting 
total cells recovered in BAL fluid with a hemocytometer.  Results showed characteristic 
increases in total inflammatory cells in Ada -/- versus Ada + mice, and a significant reduction 
between Ada/Opn -/- and Ada -/- mice (Figure 3.6A).  Analysis of BAL cellular differentials 
displayed significant reductions in neutrophils and lymphocytes (Figure 3.6C, D).  These results 
suggest that OPN contributes to pulmonary inflammation in Ada -/- mice.   
OPN contributes to alveolar air-space enlargement in Ada -/- mice 
Ada -/- mice exhibit histopathologic features resembling COPD in parallel with 
upregulations in OPN (71) in alveolar macrophages.  In addition, alveolar macrophages 
isolated from smokers display upregulations in OPN (101).  To investigate OPN-dependent 
emphysematous changes, alveolar air-space size was quantified in H&E stained lung sections 
from Ada -/- and Ada/Opn -/- mice utilizing mean chord length calculations.  Results of this 
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analysis (Figure 3.7) showed typical increases in average distal air-space size of Ada -/- versus 
Ada + mice.  Furthermore, Ada -/- mice without Opn had dramatically reduced average size of 
 
Figure 3.5 - Histopathology associated with genetic removal of Opn in Ada -/- mice 
Lungs isolated from Ada +, Opn -/-, Ada -/-, and Ada/Opn -/- mice at postnatal day 37 were 
processed for sectioning and H&E staining.  Displayed sections are representative of 9-12 mice 
from each genotype.  Scale bars: 200 µm.
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Figure 3.6 - Airway inflammatory cells in Ada -/- and Ada/Opn -/- mice   
(A) BAL fluid was collected at postnatal day 37 and total inflammatory cells were counted.  (B, 
C, and D) BAL cells were cytospun and stained with Diff-Quick for the determination of cellular 
differentials.  Values given are mean cell counts + SEM.  *P < 0.05 versus Ada + mice; #P < 
0.05 versus Ada -/- mice.  n = 4 (Ada + and Opn -/-), n = 7 (Ada -/- and Ada/Opn -/-). 
 32 
 
 
 
 
Figure 3.7 - Alveolar air-space size 
in Ada -/- and Ada/Opn -/- mice  
(A) Lungs from Ada +, Opn -/-, Ada -/-, 
and Ada/Opn -/- mice at postnatal day 
37.  Scale bars: 200 µm.  (B) Average 
alveolar air-space size was determined 
using Image-Pro analysis software on 8 
images at 20X magnification per 
mouse lung.  Values are given as 
mean cord lengths in µm + SEM.  *P < 
0.05 versus Ada + mice; #P < 0.05 
versus Ada -/- mice.  Displayed images 
are representative of n = 6 mice (Ada + 
and Opn -/-); n = 8 mice (Ada -/- and 
Ada/Opn -/-). 
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alveolar air-spaces suggesting that OPN contributes to the process of distal air-space 
destruction and enlargement in the Ada -/- model.   
OPN increases mediators of air-space enlargement   
Matrix metalloproteases (MMPs) are heavily regarded as mediators of the process of 
alveolar air-space destruction leading to emphysema in patients and animal models (102-105).  
Multiple in vitro studies in cancer demonstrate that OPN increases MMP-9 activity (88-90).  A 
previous study in the Ada -/- model demonstrates increases in OPN concurrent with 
upregulations of MMP-9, MMP-12, and the corresponding tissue inhibitor of MMPs, TIMP-1 
(71).  Thus, the influence of OPN on MMP expression in the Ada -/- model was investigated.  
Transcript levels of MMP-9, MMP-12, and TIMP-1 were significantly elevated in the lungs of 
Ada -/- mice (Figure 3.8).  Expression of MMP-9 and TIMP-1 was significantly reduced in lungs 
of Ada/Opn -/- mice, but MMP-12 expression remained elevated.  Quantification of MMP-9 
immunostaining in lung sections confirmed increased levels in the lungs of Ada -/- mice and 
significant reductions in the lungs of Ada/Opn -/- mice (Figure 3.9B, D).  These findings suggest 
OPN-dependent increases in MMP-9 as a mechanism of air-space enlargement. 
OPN-dependent in vivo neutrophil recruitment   
Neutrophils are characteristically elevated in the lungs of Ada -/- mice (71) and patients 
with COPD (107, 108).  Also, neutrophils are a significant source of destructive MMPs and 
serine proteases thought to contribute to the pathogenesis of COPD (105).  Immunostaining for 
a neutrophil marker in lungs of Ada -/- mice displays extensive staining within the alveolar air-
spaces and interstitium (Figure 3.9A), a similar pattern shown in MMP-9 immunostaining 
(Figure 3.9B).  Quantification of staining in these sections confirms decreased neutrophils and 
MMP-9 protein in the alveolar air-spaces of Ada/Opn -/- versus Ada -/- mice (Figure 3.9C, D).   
Many neutrophil chemotactic cytokines are upregulated in the BAL fluid of Ada -/- mice 
(71).  Several studies site cytokine-like properties of OPN for numerous cell types (75) 
including neutrophils (109).  Thus, we sought to investigate the relative contribution of OPN 
present in BAL fluid of Ada -/- mice (Figure 3.3C) to in vivo neutrophil chemotaxis.  
Intraperitoneal (IP) administration of OPN resulted in dose-dependent increases in the number 
of neutrophils recovered from peritoneal washes (Figure 3.10A).  Similarly, BAL fluid isolated 
from Ada -/- and Ada/Opn -/- mice was administered IP and results demonstrated significantly 
fewer neutrophils recruited in the absence of OPN (Figure 3.10B).    
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Figure 3.8 - OPN-dependent regulation of air-space enlargement mediators 
Transcript levels of MMP-9, MMP-12, and TIMP-1 measured in whole-lung extracts from 
postnatal day 37 mice using quantitative RT-PCR.  Transcript levels are shown for (A) MMP-9, 
(B) TIMP-1, and (C) MMP-12.  Transcripts were measured in parallel with 18S rRNA and 
values are presented as mean normalized transcript levels (∆-ct) + SEM.  n = 6 mice (Ada -/- and 
Ada/Opn -/-); n = 3 mice (Ada + and Opn -/-).  (D) TIMP-1 activity in airways was determined with 
specific ELISA (R&D Systems) on BAL fluid collected from mouse lungs.  Data are mean + 
SEM.  n = 7 mice (Ada -/- and Ada/Opn -/-); n = 3 mice (Ada + and Opn -/-).  *P < 0.05 versus Ada 
+
 mice; #P < 0.05 versus Ada -/-. 
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Figure 3.9 - Lung neutrophil and MMP-9 immunolocalization  
Lung sections from Ada -/- and Ada/Opn -/- mice at postnatal day 37 were stained with (A) 
neutrophil specific antibody and (B) MMP-9 antibody.  Scale bars: 100 µm.  (C) Neutrophils and 
(D) MMP-9 positive cells in lung tissue were identified and counted using Image Pro analysis 
software on 20 images per mouse lung.  Data presented as mean number of positive staining 
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cells per 20X field + SEM.  *P < 0.05 versus Ada +; #P < 0.05 versus Ada -/- mice.  n = 6 mice 
(Ada -/- and Ada/Opn -/-); n = 3 mice (Ada + and Opn -/-). 
 
Figure 3.10 - OPN-mediated neutrophil recruitment in an in vivo model 
In vivo neutrophil recruitment was assessed by quantification of neutrophils migrating into the 
peritoneal cavity following intraperitoneal (IP) administration of an agent.  (A) IP injection of 
PBS (vehicle), BSA (negative protein control), CXCL1 (positive control), and increasing doses 
of OPN.  Data are mean neutrophil differentials + SEM.  *P < 0.05 versus PBS; #P < 0.05 
versus OPN 500 ng.  n = 3 mice (PBS, BSA, and CXCL-1); n = 5-7 mice (OPN 500, 1000, and 
2000 ng).  (B) Peritoneal neutrophil recruitment was measured in wild type mice following IP 
injection of BAL fluid isolated from 4 genotypes of mice at postnatal day 37.  Data are mean 
neutrophil differentials + SEM.  n = 3 (Ada + and Opn -/- BAL fluid); n = 6 (Ada -/- and Ada/Opn -/- 
BAL fluid).  (C) IP injections of OPN were preceded by IP injection of isotype control or β3 
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integrin or CD44 receptor blocking antibodies.  Data are mean neutrophil differentials + SEM.  n 
= 5 mice (PBS + Isotype and OPN + Isotype); n = 6 mice (OPN + anti-CD44); n = 7 mice (OPN 
+ anti-β3). 
OPN induces migration of numerous cell types including macrophages and lymphocytes 
through engagement of CD44 and αvβ3 integrin receptors (84).  However, OPN actions on 
neutrophils are not well-characterized.  This in vivo assay was used to determine the role of 
CD44 and β3-containing integrins in OPN-mediated neutrophil migration.  IP preadministration 
of CD44 neutralizing Ab significantly reduced neutrophils recovered from peritoneal lavage in 
response to OPN (Figure 3.10C) but did not alter CXCL-1 induced neutrophil recruitment into 
the peritoneum (data not shown).  Preadministration of β3 integrin blocking Ab also reduced 
OPN-mediated neutrophil recruitment (Figure 3.10C).  These results suggest that OPN 
engagement of both CD44 and β3 integrin-containing receptors promote recruitment of 
neutrophils in vivo.  These findings outline potential mechanisms involved in OPN-mediated 
increases in proteases present in distal air-spaces leading to the alveolar destruction seen in 
the Ada -/- model.   
CD44 expression, localization, and neutralization in Ada -/- mice 
 A genome-wide microarray screen of Ada -/- mice displayed significant elevations in 
CD44 transcripts over Ada + littermates (73).  This finding was confirmed by direct 
measurement of CD44 transcript levels from whole lung RNA isolates from Ada + and Ada -/- 
mice (Figure 3.11A).  To localize the expression of CD44 to specific cell types, 
immunohistochemistry for CD44 was performed in lung sections.  Results display ubiquitous 
expression of CD44 in multiple areas of the lung including bronchial airways, infiltrating 
inflammatory cells, and alveolar epithelial cells (Figure 3.11B).  Increased immunoreactivity for 
CD44 was noted in the bronchial epithelium and infiltrating inflammatory cells of Ada -/- versus 
Ada + mouse lungs.  This, coupled with previous results displaying CD44-dependent 
recruitment of neutrophils by OPN, suggests CD44 signaling may play a role in promoting 
pathology in the Ada -/- model.    
 To investigate the contribution of CD44 to lung pathology, Ada -/- mice maintained on 
PEG-ADA until postnatal day 25 were administered CD44 neutralizing Ab and endpoints were 
collected on postnatal day 41.  In contrast to results seen in Ada/Opn -/- mice and in vivo 
neutrophil recruitment experiments, systemic administration of CD44 blocking Ab had no 
significant effect on pulmonary inflammation and neutrophilia (Figure 3.12A, C).  These results 
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prompt repeat and alternative strategies for the investigation of CD44 in the context of 
pulmonary pathology.   
 
 
Figure 3.11 - CD44 expression in Ada -/- mice 
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(A) Transcript levels for CD44 in Ada + and Ada -/- mouse lungs at postnatal day 37.  Data 
presented as mean transcript levels normalized to 18S rRNA (∆-Ct) + SEM.  *P < 0.05 versus 
Ada + mice.  n = 6 Ada -/- mice; n = 3 Ada + mice.  (B) Lung sections processed for 
immunolocalization of CD44 (black arrows).  Scale bars: 100 µm.    
 
 
Figure 3.12 - CD44 neutralization in Ada -/- mice 
Airway inflammatory cells isolated at postnatal day 41 from Ada -/- mice administered systemic 
CD44 neutralizing antibody or isotype control versus Ada + littermates.  (A) Total inflammatory 
cell counts; (B) absolute macrophage count and (C) total neutrophils, eosinophils and 
lymphocytes isolated in BAL fluid.  Data are mean + SEM.  *P < 0.05 versus Ada + untreated 
mice.  n = 4 Ada + untreated mice; n = 8 Ada -/- isotype; n = 9 Ada -/- anti-CD44.   
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OPN and the regulation of proinflammatory cytokines 
In the setting of lung pathology, Ada -/- mice exhibit increased levels of cytokines and 
chemokines, many of which are regulated by the A2BR (71) and promote the recruitment of 
neutrophils.  To investigate if OPN-dependent recruitment of inflammatory cells is indirect 
through the upregulation of cytokines, their transcript levels were measured in whole lung RNA 
extracts from mice at postnatal day 37.  Results show characteristic increases in expression of 
proinflammatory cytokines in the lungs of Ada -/- versus Ada + mice, but no significant 
differences between Ada -/- and Ada/Opn -/- transcripts (Figure 3.13).  Although a trend decrease 
in CXCL-1 transcripts was observed in Ada/Opn -/- versus Ada -/- mice (data not shown), there 
was no difference in protein levels of CXCL-1 between the two genotypes.  These findings 
suggest that OPN does not significantly influence the levels of adenosine-regulated 
proinflammatory cytokines.  These data demonstrate that OPN promotes the recruitment of 
neutrophils through engagement of cell surface receptors and not via the regulation of other 
proinflammatory cytokines.   
OPN and peripheral blood neutrophilia 
 To examine if reductions in lung neutrophilia in the absence of OPN were due to a 
fundamental defect in granulopoiesis, circulating leukocytes were obtained and quantified in the 
peripheral blood of wild type and Opn -/- mice.  The numbers of neutrophils and other leukocyte 
populations were the same as wild type mice (Figure 3.14), suggesting neutrophil development 
is normal in Opn -/- mice.  
OPN and alveolarization 
 Developing lungs undergo secondary septation during the process of alveogenesis from 
postnatal days 5 to 10 in Ada + mice (30).  To determine if reduced alveolar air-space size in 
Ada/Opn -/- mice at postnatal day 37 was due to OPN-dependent alterations in alveogenesis, 
airspace size was quantified from H&E-stained lung sections isolated from Ada + and Opn -/- 
mice on postnatal day 10.  Results demonstrate no significant differences in air-space size 
between these two genotypes (Figure 3.15) suggesting OPN does not play a critical role in 
secondary septation of the air-spaces.  Further, Ada -/- mice display adenosine-dependent 
defects in alveogenesis in the absence of inflammation resulting in increased size of alveolar 
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air-spaces (30).  Results of this study demonstrate significantly increased alveolar air-space 
size in both Ada -/- and Ada/Opn -/- mice at postnatal day 10 (Figure 3.15).  These results  
 
Figure 3.13 - OPN-dependent regulation of proinflammatory cytokines  
(A) Protein levels of CXCL1 in BAL.  Transcript levels are shown for (B) CCL7, (C) TNF α, (D) 
CCL2, (E) CXCL2, and (F) IL-6.  Transcripts for CCL7 were measured in parallel with 18S 
rRNA and values are presented as mean %18S rRNA + SEM.  Remaining transcripts were 
normalized to 18S rRNA and are presented as mean normalized transcript levels (∆-Ct) + SEM.  
n = 4 mice (Ada+ and Opn-/-); n = 6 mice (Ada-/- and Ada/Opn-/-).  *P < 0.05 versus Ada+ mice. 
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Figure 3.14 - Quantification of blood leukocytes in Opn -/- mice  
Peripheral blood leukocytes were isolated and counted from Ada + and Opn -/- mice at postnatal 
day 37.  Data presented are mean cell counts + SEM.  n = 4 mice per genotype.   
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Figure 3.15 - OPN and alveolarization 
(A) Lungs from Ada +, Opn -/-, Ada -/-, and 
Ada/Opn -/- mice at postnatal day 10.  Scale 
bars: 200 µm.  (B) Average alveolar airway 
size was determined using Image-Pro 
analysis software on 16 images at 10X 
magnification per mouse lung.  Values are 
given as mean cord lengths in µm + SEM.  
*P < 0.05 versus Ada + mice.  Displayed 
images are representative of n = 8 mice 
(Ada + and Opn -/-); n = 10 Ada -/- mice; n = 
6 Ada/Opn -/- mice. 
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indicate that OPN does not contribute to normal or pathologic development of the alveolar air-
spaces.   
OPN-mediated angiogenesis in Ada -/- mice 
Previous work has shown that symptomatic Ada -/- mice display increased pulmonary 
angiogenesis (28).  Enhanced angiogenesis has also been described in association with air-
space destruction seen in COPD and ARDS (99).  Furthermore, OPN has been shown to 
promote the process of angiogenesis (76, 81).  To determine the contribution of OPN to 
angiogenesis in the Ada -/- model, tracheal vascularity was utilized as a measure of lung 
angiogenesis (29) in Ada -/- and Ada/Opn -/- mice.  Results demonstrate a significant reduction 
in vascularity of tracheas isolated from Ada/Opn -/- mice (Figure 3.16) suggesting OPN 
contributes to lung angiogenesis, an indicator of the development of pulmonary pathology in 
this model. 
Mucus metaplasia in Ada/Opn -/- mice 
Patients with COPD, especially the chronic bronchitis subtype, exhibit mucus 
metaplasia in the large airways.  Previous studies have demonstrated increased mucus cell 
metaplasia in Ada -/- mice in parallel with increased adenosine levels and emphysema (22, 30).  
Furthermore, OPN is suggested to contribute to mucus metaplasia in a model of allergic airway 
disease (96).  Therefore, the contribution of OPN to mucus metaplasia in the Ada -/- model was 
investigated.  Results of PAS staining (Figure 3.17A) and subsequent scoring (Figure 3.17B) 
established no significant changes in large airway mucus between Ada -/- and Ada/Opn -/- mice.  
These findings suggest that OPN does not contribute to mucus metaplasia in the Ada -/- model.   
OPN-dependent airway remodeling and fibrosis 
Patients and animal models including Ada -/- mice exhibiting alveolar air-space 
enlargement also display features consistent with pulmonary fibrosis (13, 14, 26).  In addition, 
Opn -/- mice are protected from the effects of tissue fibrosis in various animal models (97, 98, 
110, 111).  Therefore, experiments were performed to determine the contribution of OPN to 
pulmonary fibrosis in Ada -/- mice.  Lungs of Ada -/- mice were noted to exhibit characteristic 
increases in collagen production indicated by α1 procollagen transcripts, increased collagen 
deposition detected by Masson’s Trichrome staining, and elevated soluble collagen in the 
airways.  These mice simultaneously display α SMA staining in the distal air-spaces indicating 
increased numbers of myofibroblasts (Figure 3.18A-D).  Surprisingly, Ada/Opn -/- displayed no  
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Figure 3.16 - Angiogenesis and OPN in the Ada -/- model  
(A) Tracheas were removed from postnatal day 37 mice and analyzed by whole mount CD31 
immunostaining for visualization of vessels.  Images shown are representative of > 6 per 
genotype.  (B) Vascularity was quantified by counting number of vessels intersecting a line 
drawn the length of a cartilage ring.  At least 8 cartilage rings per sample were analyzed.  Data 
presented as mean number of vessels per mm + SEM.  *P < 0.05 versus Ada -/-.  n = 6 mice 
(Ada -/-).  n = 7 mice (Ada/Opn -/-). 
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Figure 3.17 - Role of OPN in mucus 
production in the Ada -/- model 
(A) Mouse lungs were stained with Periodic 
Acid-Schiff (PAS) to assess for mucus 
present in the airways (arrows).  Scale 
bars: 200 µm.  (B) Mucus staining was 
quantified using Image Pro analysis 
software on composite images of all large 
airways per mouse lung section.  Data are 
mean mucus index + SEM.  *P < 0.05 
versus Ada +.  n = 4 mice (Ada + and Opn -/-
); n = 6 (Ada -/- and Ada/Opn -/-). 
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Figure 3.18 - Myofibroblasts and collagen 
Lungs assessed for (A) collagen deposition 
(light blue) with Masson’s trichrome staining 
and (B) myofibroblasts (arrows –brown) with 
α SMA immunohistochemistry.  Scale bars: 
50 µm.  Displayed sections represent > 6 per 
genotype.  (C) Transcript levels for whole 
lung α1 Procollagen.  (D) Soluble collagen 
protein present in the BAL fluid.  Transcripts 
for α1 procollagen were measured in parallel 
with 18S rRNA and values are presented as 
mean %18S rRNA + SEM.  Data for BAL 
fluid collagen displayed as mean collagen 
concentration (µg/ml) + SEM.  n = 3 mice 
(Ada + and Opn -/-); n = 6 mice (Ada -/- and 
Ada/Opn -/-).  *P < 0.05 versus Ada + mice. 
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changes in these endpoints suggesting that OPN is not required for the development of 
pulmonary fibrosis in the Ada -/- model.   
Profibrotic mediators including TGF-β1, uPA, MMP-2 and PAI-1 were also examined.  
Consistent with histologic endpoints of fibrosis, transcripts for TGF-β1, uPA, and MMP-2 were 
significantly elevated in the lungs of both Ada -/- and Ada/Opn -/- mice (Figure 3.19 A-C).  
However, while the lungs of Ada -/- mice displayed significant increases in PAI-1, expression in 
Ada/Opn -/- was significantly reduced (Figure 3.19D) suggesting OPN influences lung PAI-1 
levels.   
Finally, the production of fibronectin, an ECM protein, is regulated by adenosine 
signaling (112) and is increased in association with inflammation and air-space destruction 
seen in conditions such as COPD (113) and ARDS (99).  Increased fibronectin deposition in 
distal air-spaces is also associated with pulmonary fibrosis.  Production and deposition of 
fibronectin was elevated in Ada -/- mice, but these endpoints were substantially reduced in 
lungs of Ada/Opn -/- mice (Figure 3.20A, B) suggesting OPN-dependent regulation of fibronectin 
expression and/or deposition.  Taken together, while it appears that OPN is not necessary for 
the development of major indices of pulmonary fibrosis in the lungs of Ada -/- mice, OPN does 
regulate other mediators and endpoints commonly associated with its progression. 
OPN expression, localization, and association with severity of COPD in humans  
Ada -/- mice exhibit features consistent with COPD including pulmonary inflammation 
and alveolar air-space destruction and remodeling in parallel with increased OPN expression 
(71) within alveolar macrophages.  A microarray screen of alveolar macrophages isolated from 
smokers identified elevated expression of OPN that correlated with degree of airway 
obstruction (101).  However, the levels of OPN in COPD patients with emphysema have not 
been examined.  Immunolocalization of OPN expression in patients with COPD was localized 
to infiltrating cells within the alveolar air-spaces (Figure 3.21A) consistent with findings in the 
Ada -/- model.  While OPN staining was present in lungs of Stage 0 COPD patients, relatively 
little was present on infiltrating cells.  To quantify differences in OPN expression in patients with 
COPD, transcript levels were measured in whole lung RNA extracts from patients with Stage 4 
COPD and Stage 0.  Results demonstrate minimal differences in the expression of OPN in the 
whole lungs of patients with Stage 4 versus Stage 0 (Figure 3.21B).  However, quantification of 
OPN positive cells in lung sections revealed dramatic increases in Stage 4 patients versus  
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Figure 3.19 - Profibrotic mediators  
Transcript levels of mediators of airway remodeling and fibrosis were measured using 
quantitative RT-PCR.  Transcript levels are shown for (A) TGF-β1, (B) uPA, (C) MMP-2, and (D) 
PAI-1.  Transcripts were normalized to 18S rRNA and are presented as mean normalized 
transcripts (∆-Ct) + SEM.  n = 3 mice (Ada + and Opn -/-); n = 6 mice (Ada -/- and Ada/Opn -/-).  *P 
< 0.05 versus Ada + mice.  #P < 0.05 versus Ada -/- mice.  
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Figure 3.20 - Fibronectin 
(A) Fibronectin immunofluorescence on lung sections at postnatal day 37 and corresponding 
(B) whole lung fibronectin transcript levels.  Scale bars: 100 µm.  Fibronectin transcripts were 
normalized to 18S rRNA and are presented as mean normalized transcript levels (∆-Ct) + SEM.  
n = 3 mice (Ada + and Opn -/-); n = 6 mice (Ada -/- and Ada/Opn -/-).  *P < 0.05 versus Ada + 
mice.  #P < 0.05 versus Ada -/- mice. 
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Figure 3.21 - OPN expression in patients with COPD 
(A) Immunolocalization of OPN expression within infiltrating cells present in alveolar airways 
(arrows) of patients with COPD stage 0 and stage 4 using GOLD criteria.  Scale bars: 100 µm.  
(B) Transcript levels of OPN in patients at stage 0 vs. 4.  Transcripts for OPN were measured 
in parallel with 18S rRNA and values are presented as mean %18S rRNA + SEM.  n = 4 (Stage 
0); n = 9 (Stage 4).  (C) OPN positive staining cells within alveolar airways were quantified on > 
12 images per patient lung.  Data presented as mean number of positive staining cells per 10X 
field + SEM.  n = 4 (Stage 0); n = 10 (Stage 4).  *P < 0.05 versus Stage 0.   
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Stage 0 (Figure 3.21C).  These results indicate increased OPN-positive infiltrating inflammatory 
cells in patients with COPD, similar to the Ada -/- model.  Finally, number of OPN-positive cells 
in patient samples was associated with degree of airway obstruction measured by forced vital 
capacity (FVC), forced expiratory volume in one second (FEV1), and peak expiratory flow rate 
(PEFR) (Figure 3.22).  Collectively, the results of this study describe the importance of 
increased OPN in the lungs leading to the development of emphysema in patients with COPD. 
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Figure 3.22 - OPN expression 
associates with clinical 
indicators of COPD 
Association of number of OPN 
positive staining cells with disease 
severity represented by (A) forced 
vital capacity (FVC), (B) forced 
expiratory volume in one second 
(FEV1), and (C) peak expiratory 
flow rate (PEFR).  n = 4 (Stage 0); 
n = 8 (Stage 4). 
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Chapter 3 - Discussion 
A well-established model displaying the tissue destructive effects of chronic adenosine 
elevations is the Ada -/- mouse (30, 114).  These mice exhibit a pulmonary phenotype 
consisting of pulmonary inflammation, alveolar air-space destruction, mucus metaplasia, and 
pulmonary fibrosis.  Recent studies have suggested that signaling through the A2BR represents 
a major mechanism involved in disease progression in this model (71).  Furthermore, these 
studies also revealed that these mice will concurrently exhibit A2BR-dependent upregulations in 
OPN, a protein implicated in various pathologic conditions which include inflammation and 
fibrosis.  Therefore, it was hypothesized that OPN contributes to the pulmonary phenotype in 
Ada -/- mice.  To test this, Ada/Opn -/- mice were generated and pulmonary endpoints were 
examined.  Genetic removal of Opn in Ada -/- mice dramatically reduced features of chronic 
lung disease including pulmonary inflammation and alveolar air-space enlargement.  Most 
endpoints consistent with pulmonary fibrosis were unchanged in Ada/Opn -/- lungs.  The results 
of this study demonstrate that OPN regulates the process of inflammation and alveolar air-
space enlargement in the setting of elevated adenosine levels (Figure 3.23).  Similarities 
between Ada -/- mice and humans with chronic lung disease demonstrate that the Ada -/- mouse 
is a useful model to guide the development of therapeutic targets for these conditions.   
Ada -/- mouse lungs display an inflammatory cell infiltrate consisting of alveolar 
macrophages, lymphocytes, and neutrophils (19, 26).  OPN has well-described chemotactic 
properties for these cell types (84, 86, 87, 93, 109).  Consistent with this, these results 
demonstrate that genetic removal of OPN in Ada -/- mice reduced pulmonary neutrophilia 
(Figure 3.6C).  These changes were found to be independent of OPN-mediated changes in 
proinflammatory cytokines (Figure 3.13) and alterations in peripheral blood neutrophilia (Figure 
3.14).  Furthermore, these results demonstrate using an in vivo assay of neutrophil recruitment 
that OPN is a significant contributor to neutrophil chemotaxis (Figure 3.10B) among several 
cytokines upregulated in Ada -/- mouse lungs.  OPN-mediated chemotaxis of several cell types 
is dependent on OPN binding to cell surface receptors CD44 (75, 83, 85, 86) and αvβ3 (80, 82, 
115).  This in vivo assay demonstrated that OPN-mediated neutrophil recruitment can be 
inhibited by blocking interactions with these receptors (Figure 3.10C).  Thus, these receptors 
may contribute to OPN-dependent neutrophil chemotaxis in the lungs of Ada -/- mice.   
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Ada -/- mice develop alveolar air-space enlargement resembling histological findings of 
patients with emphysema (30, 71).  A major observation of this study was that Ada/Opn -/- mice  
 
Figure 3.23 - Schematic representation of OPN-mediated air-space enlargement 
Repeated tissue injury results in chronic elevations in extracellular adenosine levels.  As a 
result, A2B adenosine receptors on macrophages are engaged promoting the upregulation and 
secretion of OPN.  This promotes the recruitment of neutrophils via chemotaxis through 
engagement of cell surface receptors CD44 and αvβ3 integrin.  Increased neutrophils in the 
distal airways release proteases including MMP-9 leading to the destruction and enlargement 
of alveolar air-spaces. 
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had dramatically reduced size of alveolar air-spaces compared to Ada -/- mice (Figure 3.7).  
Microarray analysis of alveolar macrophages isolated from smokers identified upregulations in 
OPN and found it was the only protein that correlated with severity of airway obstruction (101).  
Results of our studies demonstrate that the majority OPN immunolocalization in human COPD 
lung samples is present in alveolar macrophages (Figure 3.21) and this expression is 
associated with severity of airway obstruction (Figure 3.22).  Given these findings and the 
report that adenosine levels are elevated in patients with COPD (31), our findings suggest that 
adenosine-dependent regulation of OPN may be a major driving mechanism of emphysema. 
Our studies indicate that OPN -/- mice exhibit slightly reduced air-space size at postnatal 
day 37 versus Ada + mice.  Additionally, there are reports that OPN is down-regulated in lungs 
of rats during secondary septation (116) and OPN is up-regulated in models exhibiting 
defective alveolarization (116, 117).  Collectively, this suggests that reduced OPN expression 
in air-spaces at stages of secondary septation is associated with alveolar air-space 
development resulting in smaller average air-space size.  However, Opn -/- mice display no 
significant changes in average air-space size compared to Ada + mice at postnatal day 10 
(Figure 3.15).  These results confirm that OPN does not significantly influence developmental 
alterations in air-space size and support conclusions that OPN contributes to pathologic 
enlargement of alveolar air-spaces.   
A2BR signaling has been shown to contribute to the pathogenesis of emphysema in the 
Ada -/- model (71).  This is in association with increases in recruitment of neutrophils and 
macrophages as well as upregulations of MMP-9, MMP-12, TIMP-1 and OPN.  These results 
indicate that OPN is a significant mediator of alveolar air-space destruction downstream of 
A2BR signaling given that Ada/Opn -/- mice are protected from A2BR-mediated air-space 
enlargement and display reductions in neutrophils and MMP-9 (Figure 3.9).  Though these 
findings do not address or rule out the contribution of alveolar macrophages or MMP-12 to the 
development of emphysema in this model, they do suggest that OPN-dependent changes in 
air-space size are a result of pulmonary neutrophilia and increased activity of MMP-9.  This is 
consistent with reports (88, 89) on mechanisms OPN-mediated malignant transformation 
describing OPN signaling through the αvβ3 integrin receptor leading to increased activation of 
MMP-9.  Furthermore, elevations in OPN are described in other disease processes such as 
ARDS (99, 118) and bronchiolitis obliterans (100) which display influx of neutrophils and MMP-
9 in association with alveolar air-space destruction and remodeling.  Also, neutrophils have a 
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well-recognized role in the pathogenesis of emphysema (119).  Taken together, this supports 
the model that A2BR-dependent upregulations of OPN result in increased chemotaxis of 
neutrophils leading to MMP-9 mediated alveolar air-space destruction.   
Finally, in addition to enhanced OPN expression and air-space destruction, Ada -/- mice 
and patients with COPD and ARDS all display associated increases in pulmonary angiogenesis 
(99).  The finding of reduced angiogenesis in Ada/Opn -/- mice is supported by the established 
role of OPN and the αvβ3 receptor in the process of angiogenesis (76, 81).  These results 
display additional evidence for reduced lung pathology in the absence of OPN and potentially 
suggest an additional role of OPN-dependent angiogenesis in adenosine-mediated lung 
pathology.   
Overall, these findings clearly indicate OPN is a physiologically relevant mediator of 
neutrophil chemotaxis and outline a mechanism for OPN-driven emphysema in the lung.  An 
attempt to display contribution of CD44 signaling to pulmonary neutrophilia and emphysema in 
the Ada -/- model was inconclusive (Figure 3.12).   However, it is well-established that the 
putative OPN receptors CD44 and αvβ3 are an integral part of OPN-driven inflammatory and 
malignant pathogenesis and pharmacologic therapies targeting these receptors for these 
conditions have been developed (120, 121).  Only recently are these receptors and OPN 
realized to function in a similar fashion to drive the pathogenesis of acute and chronic lung 
disease.  Hence, it is clear that further investigation of CD44 and αvβ3 in the pathogenesis of 
COPD and other chronic lung diseases is warranted.    
Other phenotypic features consistent with COPD in Ada -/- mice include mucus 
metaplasia (30).  It has been reported previously that engagement of the A3 adenosine receptor 
is responsible for mucus metaplasia in Ada -/- mice (22).  However, recent studies in models of 
allergic airway disease demonstrated that genetic removal of OPN protected mice from 
inflammation and mucus production (96, 106).  Our findings indicate that while genetic removal 
of OPN attenuated pulmonary inflammation, mucus production was unchanged (Figure 3.17).  
This suggests that elevated adenosine levels engage other pathways leading to mucus 
metaplasia in this model.   
Another feature of Ada -/- mice is the development of pulmonary fibrosis (26) 
characterized by increased collagen production and deposition in association with 
myofibroblasts within fibrotic foci in the distal air-spaces (122).  In conjunction with these 
pathologic changes are elevated profibrotic mediators including TGF-β1, MMP-2, PAI-1, and 
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uPA.  Several recent publications report that Opn -/- mice are protected from tissue fibrosis (97, 
98, 110, 111) and there is suggestion that OPN directs the differentiation of fibroblasts into 
myofibroblasts (123).  While genetic removal of Opn in Ada -/- mice largely resolved features of 
emphysema, major indices of pulmonary fibrosis were unchanged.  Specifically, Ada -/- and 
Ada/Opn -/- mice both exhibited increased soluble collagen, collagen production and deposition 
within fibrotic foci represented by increased α SMA staining within the distal air-spaces (Figure 
3.18).  Furthermore, there were no differences in major profibrotic mediators TGF-β1, MMP-2, 
and uPA associated with the genetic removal of Opn in Ada -/- mice (Figure 3.19A-C).  These 
results suggest that OPN is not required for the development of pulmonary fibrosis in the Ada -/- 
model.   
In contrast, expression of PAI-1, a protease inhibitor implicated in the pathogenesis of 
fibrosis (124), was reduced in Ada/Opn -/- mice (Figure 3.19D).  This is consistent with reports 
that elevated systemic concentrations of PAI-1 are reduced in Opn -/- mice (125).    While the 
genetic removal of Opn in Ada -/- mice did not affect the number of myofibroblasts or production 
and deposition of collagen, significant reductions were observed in fibronectin expression and 
deposition (Figure 3.20).  Consistent with OPN-dependent changes in air-space enlargement, 
increased detection of extracellular matrix proteins, including collagen and fibronectin, are 
associated with inflammation-driven alveolar destruction seen in animal models (126) and in 
patients with COPD (113), ARDS (99), and bronchiolitis obliterans (127).  These results 
suggest that OPN selectively drives the expression of fibronectin in the lungs of Ada -/- mice.  
Similarly, it may be interpreted that fibronectin expression is relatively sensitive to changes in 
inflammation-mediated alveolar air-space damage and that overriding profibrotic mechanisms 
driving the production of collagen exist independent of inflammation and OPN expression.  
These findings provide important insight into the potential disconnect between inflammation 
and the onset of fibrosis.  In summary, despite evidence revealing OPN is not required for the 
development of fibrosis in this model, we observed OPN may contribute to select features and 
may be a beneficial therapeutic target for pulmonary fibrosis at certain stages of disease.   
 In conclusion, results of this study demonstrate in vivo OPN-mediated recruitment of 
neutrophils, protease activation, and angiogenesis.  These findings are consistent with the 
hypothesis that OPN contributes to the pulmonary phenotype in Ada -/- mice.  This body of work 
was the first report of OPN-dependent alveolar air-space destruction and enlargement.  
Furthermore, this work was the first to demonstrate elevated OPN expression in patients with 
the emphysema subtype of COPD.  Drugs targeting the A2B adenosine receptor, CVT-6883, 
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and neutrophil-recruiting chemokines and their receptors are currently in different phases of 
clinical trials for the treatment of COPD/emphysema (128, 129).  The results of this study will 
guide the school of thought that A2BR signaling and neutrophil trafficking are important in the 
onset and progression of this condition.  This will aid future neutrophil-targeted and A2BR-based 
therapeutics for the treatment of COPD.  Finally, given the ability of OPN to regulate multiple 
processes promoting the pathogenesis of COPD, this study introduces OPN as an attractive 
biomarker candidate to follow disease progression or a therapeutic target in the treatment of 
these patients. 
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Chapter 4 - Introduction  
Pulmonary fibrosis 
Pulmonary fibrosis is a histopathologic feature of chronic lung diseases of the 
interstitium affecting the large and small airways and distal air-spaces of at least 200,000 
Americans (15, 16).  Particularly severe forms, such as idiopathic pulmonary fibrosis (IPF) carry 
a mean survival rate of 3-5 years (130) and the only available treatment is lung transplantation.  
Changes associated with fibrosis include distorted lung architecture and excessive, 
dysregulated deposition of collagen which impairs gas exchange.  Repeated, often insidious 
tissue injury leading to chronic inflammation is thought to be the origin of fibrosis.  In fact, many 
similarities exist between pathways and cell types activated during normal wound healing and 
fibrosis.  Full understanding of how these pathways shift away from normal healing toward 
fibrosis will ultimately further knowledge of its pathogenesis and hopefully lead to adequate 
management of these devastating conditions.   
Normal wound healing is a temporal process encompassing the recruitment and 
activation of several different cell types (8, 131).  Epithelial and endothelial cell damage recruits 
platelets to the site of injury providing the initial fibrin clot, hemostasis, and the release of 
cytokines, chemokines and growth factors.  These factors induce chemotaxis, permeabilization 
and regional vasodilation to facilitate inflammatory cell influx.  These cells secrete antimicrobial 
agents and remove invading organisms, damaged host tissue, and foreign debris.  Angiogenic 
factors are also secreted stimulating the migration endothelial cells and neovascularization.  
Inflammatory cells also secrete profibrotic factors such as PAI-1, IL-13, PDGF, IL-6, and TGF-β 
that promote the activation, migration, and differentiation of various cell types and the formation 
of myofibroblasts.  These cells secrete ECM and promote contraction of tissue at the wound 
site to facilitate closure and re-epithelialization.  Proper degradation of deposited ECM by 
matrixmetalloproteases and departure of myofibroblasts from the repair site are necessary 
steps to finalize the wound healing process.   
For reasons poorly understood, in the setting of chronic inflammation and repeated 
tissue injury, there is a shift toward excessive production of profibrotic mediators leading to 
enhanced formation and survival of myofibroblasts (8, 18).  This ultimately promotes 
progressive accumulation of collagen and the development of fibrosis.  Investigation into 
aberrations in the wound healing process and the regulation of myofibroblast biology is an area 
of intense investigation in hopes of developing therapeutic targets to halt and/or reverse the 
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progression of fibrosis.  Recent studies demonstrate that a subset of the myofibroblast 
population in pulmonary fibrosis arises from bone marrow progenitor cells known as fibrocytes 
(132, 133).  These cells express collagen and localize to the lung in response to injury.  
Pharmacologic and adoptive transfer studies have demonstrated that fibrocytes contribute to 
the pathogenesis of pulmonary fibrosis.  Other proposed sources of myofibroblasts arise from 
differentiation of resident cell types in the lung in response to changes in the tissue milieu 
following long-standing injury.   
TGF-β in pulmonary fibrosis 
As previously mentioned, numerous cytokines, chemokines, and growth factors are 
released from resident and inflammatory cells following injury.  During the acute stages of 
inflammation, TGF-β interestingly serves an anti-inflammatory role during clearance of 
apoptotic cells (134, 135).  However, in scenarios of sustained tissue injury and prolonged 
release of TGF-β, there is a shift from anti-inflammatory to a profibrotic role (136-138).  
Elevations in TGF-β are reported in patients with IPF (139) and animal models of pulmonary 
fibrosis.  TGF-β over-expression worsens fibrosis and blocking TGF-β interactions with its 
receptor prevents fibrosis in animal models.  Naturally, tissue injury increases production of 
TGF-β prior to measurable increases in extracellular matrix.  Furthermore, TGF-β is sufficient to 
promote the differentiation (140) and survival of myofibroblasts and is a potent stimulator of 
extracellular matrix production and deposition (141).  Finally, TGF-β stimulation of alveolar 
epithelial cells increases production of mesenchymal markers such as vimentin, N cadherin, 
type I collagen, and α smooth muscle actin and decreases expression of epithelial cell markers.  
These findings demonstrate that TGF-β induces pulmonary fibrosis by increasing 
myofibroblasts in alveolar airways through differentiation of fibroblasts and epithelial to 
mesenchymal transition.   
Epithelial to mesenchymal transition (EMT) 
Epithelial cells characteristically have cell polarity and cell-to-cell adhesion creating 
barriers or surfaces for absorption.  In contrast, mesenchymal cells have diminished cell-to-cell 
contact, reduced polarity, and have a propensity for migration and invasion.  The transition 
between these two cell types, EMT, is a regulated process occurring in normal and pathologic 
scenarios.  This phenotypic change in cells is required in all organisms for migration of cells in 
developing tissue structure in embryos.  Cancer cells undergoing malignant transformation 
destabilize cell-to-cell junctions and acquire a more invasive, mesenchymal phenotype to 
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facilitate migration and metastasis away from primary tumors.  Epithelial cells adjacent to 
wounded tissue acquire migratory and mesenchymal characteristics consistent with EMT to 
facilitate wound closure (142, 143).  Similarly, lineage-tracing in transgenic mice also indicates 
that hepatocytes undergo EMT during liver fibrosis (144), as do the alveolar epithelial cells 
during the pulmonary fibrosis induced by TGF-β (145) contributing to the population of 
myofibroblasts in fibrotic foci (146).      
Epithelial and mesenchymal cells characteristically display differential expression of 
proteins which function to promote the aforementioned phenotypic differences between the two 
cell types.  Regulation of proteins involved in stabilization of epithelial cell-to-cell junctions and 
reorganization of the actin cytoskeleton are key processes in the transition of epithelial cells to 
a mesenchymal phenotype.  Cadherins are a family of proteins which play a direct role in these 
functions facilitating EMT.  Results outlined later in this chapter will demonstrate a novel role for 
cadherin 11 (CDH11) in promoting pulmonary fibrosis through the regulation of EMT.   
Cadherins and EMT 
Cadherins are a group of transmembrane glycoproteins known for mediating calcium-
dependent homophilic cell-to-cell adhesion at points of cell-cell contact known as adherens 
junctions (147).  The cadherin cytoplasmic tail is a highly conserved region which interacts with 
β-catenin.  In conjunction, α catenin may bind with β catenin providing a functional link between 
cadherins and the actin cytoskeleton.  Through this, cadherins are regulators of cell shape, 
polarization, cell junction stability, and tissue architecture (147).  During embryogenesis, 
cadherins dictate patterns of cell differentiation, morphogenesis, migration and invasion.  
Similar cadherin-dependent functions play a critical role in certain pathologies exhibiting EMT 
such as cancer. The most widely studied of these are E cadherin (Cadherin 1) and N cadherin 
(Cadherin 2).    
E cadherin, typically found in epithelial cells, is localized to adherins junctions and plays 
a pivotal role in the structural maintenance of the epithelial cell lining in a variety of tissues.  N 
cadherin is the protypical mesenchymal-type cadherin typically expressed in motile and 
invasive cell types including fibroblasts, epithelial cells undergoing EMT, and invasive cancers 
(148).  Disruption of E cadherin function through down-regulation or knockdown of cancer cells 
in vitro leads to diminished cell-to-cell contact, disruption of typical epithelial cell organization, 
and increased migratory and invasive capacity (149, 150).  It follows that poorly differentiated, 
invasive cancers characteristically show reduced expression of E cadherin.  In contrast 
expression of N cadherin correlates with migratory and invasive capacity of cancers in vivo and 
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in vitro (151).  Thus, these genetic reprogramming events are hallmarks of EMT-dependent 
tumor progression.  It follows that loss of E cadherin (152-154) and gain of N cadherin (145, 
155) in cells of epithelial origin translate to EMT in fibrosis of multiple organs including the lung. 
Cadherin 11 (CDH11) 
CDH11 is another mesenchymal cadherin and expression is associated with 
mesenchymal morphogenesis, motility, and invasion.  Namely, during development increased 
CDH11 expression correlates with cell migration and outgrowth (156).  CDH11 is also 
preferentially expressed in migratory and invasive breast cancer cell lines (157).  Finally, 
CDH11 is present on fibroblast-like synoviocytes in the joint (158) and promotes the invasive 
behavior of these cells in a model of rheumatoid arthritis (159) contributing to its overall 
pathogenesis (23).  These findings suggest that CDH11 influences a specific invasive and 
mesenchymal phenotype in cells and if extrapolated to lung epithelial cells, is consistent with 
the process of EMT.  However, the role of this specific cadherin in the process of lung EMT has 
not been investigated.   
 In addition, there is evidence to suggest that CDH11 may also be important in the 
differentiation of myofibroblasts.  CDH11 is increased at sites of wound healing (160) 
suggesting its role in the physiology of myofibroblasts during repair of injured tissue.  This was 
corroborated with the detection of increased CDH11 in subcutaneous and lung fibroblasts 
stimulated with TGF-β to differentiate into myofibroblasts.  Further, CDH11 is increased in 
biopsies taken from fibrotic skin of patients with scleroderma versus normal tissue (161, 162).  
Thus, CDH11 is upregulated during normal wound healing and pathologic skin fibrosis, yet its 
role in pulmonary fibrosis has not been examined.   
These findings led to the hypothesis that cadherin 11 contributes to the 
pathogenesis of pulmonary fibrosis.  To address this, utilizing both genetic and 
pharmacologic approaches, we examined the contribution of CDH11 to the standard bleomycin 
model of pulmonary fibrosis.  Further, we examined the expression of CDH11 in various 
samples obtained from patients with IPF.  CDH11 expression was demonstrated in two cell 
types in lungs of the bleomycin model and patients with IPF: alveolar macrophages and 
hyperplastic airway epithelial cells.  In addition, the contribution of CDH11 to EMT was 
examined in an in vitro model. The results of this study demonstrate that both of these cell 
types contribute to CDH11-dependent pulmonary fibrosis through the regulation of EMT and 
TGF-β production. 
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Chapter 4 - Results 
 
Expression and localization of CDH11 in patients with ILD 
To address the role of CDH11 in pulmonary fibrosis, Cdh11 transcripts and CDH11 
protein were examined in IPF patients with severe airway restriction versus IPF patients with 
normal lung function (Figure 4.1A,B).  Immunolocalization was performed to determine cell 
types expressing CDH11 in lungs of patients with IPF.  The cell type expressing CDH11 
identified in both mild (Figure 4.1C) and severe IPF patients (Figure 4.1E) was the alveolar 
macrophage, while only severe IPF patients displayed expression in hyperplastic alveolar 
epithelial cells (AECs) adjacent to fibrotic foci (Figure 4.1D).  These results indicate an 
association of CDH11 expression with disease severity.  Further, CDH11 immunolocalization in 
hyperplastic AECs and alveolar macrophages directed subsequent studies of these cell types 
to ascertain the potential function of CDH11 in fibrosis.    
Expression and localization of CDH11 in bleomycin model of pulmonary fibrosis 
 The intratracheal bleomycin model is the most commonly utilized animal model to study 
mechanisms of pulmonary fibrosis.  To examine the contribution of CDH11 to this model, initial 
characterization included RNA, protein levels, and immunolocalization for CDH11 in wild type 
mice given intratracheal saline and bleomycin.  While results of whole lung Cdh11 mRNA 
expression demonstrate no differences at day 21 between saline and bleomycin (Figure 4.2A), 
western blot indicates increased protein levels of CDH11 in mice given bleomycin (Figure 
4.2B).  Similar to findings in patients with IPF, immunohistochemistry on lungs from mice given 
bleomycin displays CDH11 in hyperplastic AECs and alveolar macrophages (Figure 4.2D).  
These results demonstrate similarities between this mouse model and humans and support 
analysis of these cell types in addressing the mechanism of CDH11-dependent fibrosis. 
Immunofluorescence detection of CDH11 on alveolar macrophages 
Findings in lung sections of patients with IPF and mice given bleomycin indicate 
immunolocalization of CDH11 to alveolar macrophages.  This is the first indication of CDH11 
expression on any cell of hematopoietic origin.   Therefore, to carefully examine CDH11 
expression on alveolar macrophages, cytospins obtained from BAL fluid of a patient with ILD 
were incubated with N cadherin Ab (Figure 4.3B), two CDH11 Abs recognizing different 
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domains (Figure 4.3C,D), and a corresponding isotype control (Figure 4.3A).  Results 
demonstrate very low baseline levels of fluorescence in the N cadherin cytospin versus isotype  
 
Figure 4.1 - Cadherin 11 expression and immunolocalization in human IPF patients 
(A) Quantitative RT-PCR measuring Cdh11 transcripts present in RNA isolates from biopsies 
taken from IPF patients with mild and severe airway restriction.  Transcripts for Cdh11 were 
measured in parallel with PPIA and values are presented as mean normalized transcript levels 
(∆-Ct) + SEM.  n = 10 (mild IPF); n = 10 (severe IPF).  *P < 0.05 versus mild IPF. 
Immunolocalization for CDH11 in representative lung sections of (C) mild IPF and (D,E) severe 
IPF patients.  Arrows denote staining present in (C,E) alveolar macrophages and (D) 
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hyperplastic alveolar epithelial cells.  Scale bars = 100 µm.  Displayed sections are 
representative of n = 10 (mild IPF) and n = 10 (severe IPF). 
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Figure 4.2 - Cadherin 11 expression and localization in bleomycin-induced fibrosis 
(A) Quantitative RT-PCR measuring Cdh11 transcripts present in whole lung RNA isolates from 
mice at day 21 after intratracheal saline and bleomycin.  Transcripts for Cdh11 were measured 
in parallel with PPIA and values are presented as mean normalized transcript levels (∆-Ct) + 
SEM.  n = 5 (saline); n = 5 (bleomycin).  (B) Western blot for CDH11 from lung homogenates 
isolated from mice given bleomycin and saline.  Immunolocalization for CDH11 in 
representative lung sections of (C) saline (D) bleomycin-treated mice.  Arrows denote staining 
present in alveolar macrophages and hyperplastic alveolar epithelial cells.  Scale bars = 50 µm.  
Displayed sections are representative of n = 12 (saline) and n = 20 (bleomycin).   
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Figure 4.3 - CDH11 
immunolocalization on 
alveolar macrophages 
Immunofluorescence 
detection of CDH11 on BAL 
cytospins.  Cells isolated 
from a patient with ILD 
(scleroderma) stained with 
(A) isotype control, (B) N 
cadherin, (C) CDH11 
(invitrogen), and (D) 
CDH11 (23C6) antibodies.  
(E) Cells from a patient with 
IPF stained with CDH11 
(23C6) antibody.  Cells 
from mouse given 
bleomycin stained with (F) 
isotype control and (G) 
CDH11 (23C6) antibodies.  
Confocal imaging of cells 
stained with CDH11 (23C6) 
antibody isolated from a 
patient with (H) ILD 
(scleroderma), (I) IPF, and 
(J) mouse given bleomycin.  
Scale bars = 50 µm. 
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control, but increased fluorescence in cytospins stained with both CDH11 Abs further 
suggesting alveolar macrophages specifically express CDH11.  In a similar manner, cytospins 
obtained from a patient with IPF (Figure 4.3E) and from mice given bleomycin (Figure 4.3G) 
demonstrate immunofluorescence activity for CDH11 on alveolar macrophages.    Detailed 
examination of alveolar macrophages isolated from BAL taken from patients with ILD (Figure 
4.3H), IPF (Figure 4.3I), and mice given bleomycin (Figure 4.3J) demonstrates specific 
expression of CDH11 on alveolar macrophages localized to the cell membrane by confocal 
microscopy.  These results strongly suggest CDH11 expression on alveolar macrophages.   
Contribution of CDH11 to features of pulmonary fibrosis 
CDH11 confers a mobile, invasive phenotype to key cell types involved in pathologies 
such as cancer and rheumatoid arthritis.  In addition, CDH11 is upregulated in skin biopsies 
exhibiting fibrosis and in fibroblasts stimulated to differentiate into myofibroblasts.  Results 
above indicate increased CDH11 expression in lungs of patients with IPF and mice with 
bleomycin-induced fibrosis.  To examine the contribution of CDH11 to pulmonary fibrosis, 
intratracheal bleomycin was administered to mice lacking Cdh11 (Cdh11 -/-).  All endpoints 
were assessed at 21 days after bleomycin installation.  Results of H&E staining display no 
detectable difference in pulmonary histology between wild type (WT) and Cdh11 -/- mice given 
saline (Figure 4.4).  Examination of lung sections from WT mice given bleomycin displays 
standard histopathologic features consistent with pulmonary fibrosis including inflammation, 
fibrotic foci disrupting normal alveolar architecture (Figure 4.4), and increased collagen (Figure 
4.5A) and myofibroblasts (Figure 4.5B) in the alveolar air-spaces.  These histologic endpoints 
are substantially reduced in Cdh11 -/- mice (Figure 4.4, 4.5).  Quantifiable endpoints consistent 
with pulmonary fibrosis such as soluble collagen (Figure 4.6A) and Ashcroft scoring (Figure 
4.6B) display typical increases in wild type mice given bleomycin versus saline and significant 
reductions in these endpoints in Cdh11 -/- mice given bleomycin.  Collectively, these results 
suggest that CDH11 contributes to the pathogenesis of pulmonary fibrosis.   
Systemic delivery of CDH11 blocking Ab improves established pulmonary fibrosis 
  Our results display that Cdh11 -/- mice demonstrate reduced fibrosis in response to 
bleomycin challenge.   Well-documented studies indicate pulmonary fibrosis in the bleomycin 
model is established at least seven days after bleomycin installation (163).  Therefore, to 
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determine if mice with established fibrosis can be successfully treated by targeting CDH11, wild 
type mice were administered one of two systemic CDH11 blocking Abs (clone 23C6 or 13C2)  
 
 
Figure 4.4 - Cadherin 11-dependent histopathology 
Histopathologic changes in bleomycin-induced pulmonary fibrosis associated with the genetic 
removal of Cdh11.  Lungs were taken from mice 21 days after 3.5U bleomycin installation and 
processed for sectioning and H&E staining.  Scale bars = 500 µm.  Sections are representative 
of n = 6 WT saline, n = 6 Cdh11 -/- saline, n = 13 WT bleomycin, n = 11 Cdh11 -/- bleomycin.   
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Figure 4.5 - Histologic evidence of CDH11-dependent myofibroblast formation and 
collagen deposition 
WT and Cdh11 -/- mouse lungs given bleomycin stained for (A) collagen deposition (Masson’s 
Trichrome stain) and (B) myofibroblasts (α SMA immunohistochemistry).  Scale bars = 200 µm.  
Sections are representative of n = 13 WT bleomycin, n = 11 Cdh11 -/- bleomycin. 
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Figure 4.6 - Quantifiable fibrotic endpoints associated with genetic removal of Cdh11 
Fibrosis was quantified by determination of (A) BAL collagen via colorimetric assay and (B) 
Ashcroft scoring on H&E stained lung sections.  Scores were determined on 20 images per 
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mouse lung.  n = 6 WT saline, n = 6 Cdh11 -/- saline, n = 13 WT bleomycin, n = 11 Cdh11 -/- 
bleomycin.  *P < 0.05 versus WT saline; #P < 0.05 versus WT bleomycin.  
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beginning 10 days after bleomycin installation (Figure 2.1).  Lung sections stained with H&E 
(Figure 4.7), masson’s trichrome (Figure 4.8A), and α SMA immunohistochemistry (Figure 
4.8B) all demonstrate markedly reduced histopathology in mice receiving bleomycin plus 23C6 
or 13C2 versus mice receiving isotype control Ab.  Similarly, soluble collagen levels in mice 
treated with CDH11 Abs were significantly reduced (Figure 4.8C).  These results confirm 
findings in Cdh11 -/- mice that CDH11 contributes to pulmonary fibrosis and demonstrates 
systemic delivery of CDH11 blocking Ab successfully treats established disease.   
CDH11 contributes to EMT in AECs 
 Hyperplasia is a suggested characteristic of AECs undergoing the profibrotic process of 
EMT, in vivo (154, 164, 165).  Furthermore, results demonstrate CDH11 on hyperplastic AECs 
in IPF patients (Figure 4.1D) and mice given bleomycin (Figure 4.2D) suggesting CDH11 is an 
indicator or promoter of EMT.  To confirm CDH11 expression in AECs undergoing EMT, A549 
cells were stimulated with TGF-β in vitro and endpoints consistent with EMT were measured.  
TGF-β-stimulated A549 cells demonstrate a trend decrease in E cadherin (Figure 4.9A) 
expression and expected increases in N cadherin (Figure 4.9B) and collagen production 
(Figure 4.9C).  Results demonstrate a parallel increase in Cdh11 expression (Figure 4.9D) 
consistent with findings in vivo of CDH11 immunolocalization on hyperplastic AECs (Figures 
4.1C, 4.2D).   
To determine the contribution of CDH11 to EMT, lung AECs were incubated with siRNA 
specific for Cdh11 transcripts and subsequently stimulated with TGF-β.  Findings display 
Cdh11 message was knocked down with approximately 75% efficiency (Figure 4.10A).  Cdh11 
knockdown showed a slight reversal of TGF-β-induced decrease in E cadherin (Figure 4.10B) 
and increased N cadherin expression (Figure 4.10C).  However, Cdh11 knockdown 
substantially reduced TGF-β-induced collagen expression (Figure 4.10D).  In addition, 
knockdown prevented the development of mesenchymal morphology in TGF-β-stimulated 
AECs (Figure 4.11).  These results display CDH11 contributes to pulmonary fibrosis by 
regulating the process of EMT in AECs.   
 
Role of CDH11 in pulmonary inflammation 
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 Particularly in the intratracheal bleomycin model, pulmonary inflammation precedes and 
contributes to the development of pulmonary fibrosis (163).  Additionally, inflammatory cells are 
a source of numerous profibrotic mediators, including TGF-β.  To determine the effect of 
CDH11 on pulmonary inflammation, inflammatory cells recovered (Figure 4.12) from BAL fluid  
 
Figure 4.7 - CDH11 blocking antibody improves established pulmonary fibrosis 
Histopathologic changes in bleomycin-induced pulmonary fibrosis associated with systemic 
delivery of CDH11 blocking antibody.  Mice received antibody every other day beginning 10 
days after bleomycin exposure.  Lungs were then taken at day 21 and processed for sectioning 
and H&E staining.  Scale bars = 500 µm.  Sections are representative of n = 6 saline, n = 7 
Bleo + isotype, n = 8 Bleo + 13C2, and n = 6 Bleo + 23C6.     
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Figure 4.8 - CDH11 blocking antibody 
reduces lung myofibroblasts and 
collagen 
Mouse lungs given bleomycin plus 
systemic antibody were processed and 
stained for (A) collagen deposition 
(Masson’s Trichrome stain) and (B) 
myofibroblasts (α-SMA immuno-
histochemistry).  Scale bars = 200 µm.  (C) 
Soluble collagen in BAL fluid quantified 
with colorimetric assay.  n = 6 saline, n = 7 
Bleo + isotype, n = 8 Bleo + 13C2, and n = 
6 Bleo + 23C6.  *P < 0.05 versus saline; #P 
< 0.05 versus bleomycin + isotype. 
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Figure 4.9 - TGF-β-induced EMT and Cdh11 expression in A549 lung epithelial cells 
A549 lung epithelial cells were stimulated with TGF-β (10 ng/ml) and at 24 hours, RNA was 
isolated and fold change transcripts (vs. BSA) were determined for (A) E cadherin, (B) N 
cadherin, (C) α1 pro-collagen, and (D) cadherin 11.  *P < 0.05 versus BSA.  **P = 0.06 versus 
BSA.  Data representative of 3 separate experiments.  Experiments performed by Sandeep K. 
Agarwal.   
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Figure 4.10 – Cdh11 
knockdown prevents 
TGF-β-induced EMT of 
lung epithelial cells 
A549 lung epithelial cells 
were transfected with 
Cdh11 or control siRNA, 
subsequently stimulated 
with TGF-β and at 24 
hours, RNA was isolated 
and fold change transcripts 
(vs. BSA + control siRNA) 
were determined for (A) E 
cadherin, (B) N cadherin, 
(C) α1 pro-collagen, and 
(D) cadherin 11.  Data 
representative of 3 
separate experiments.  
Experiments performed by 
Sandeep K. Agarwal.   
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Figure 4.11 - Cdh11 knockdown prevents TGF-β-induced transition to mesenchymal 
morphology in lung epithelial cells 
A549 lung epithelial cells were transfected with Cdh11 or control siRNA and subsequently 
stimulated with TGF-β.  At 24 hours cell morphology was assessed using phase contrast 
microscopy.  Experiments performed by Sandeep K. Agarwal.   
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Figure 4.12 - Contribution of CDH11 to pulmonary inflammation 
(A,D) BAL fluid was collected at day 21 after IT bleomycin and total inflammatory cells were 
counted.  (B, C, E, and F) BAL cells were cytospun and stained with Diff-Quick for the 
determination of cellular differentials.  n = 12 WT saline, n = 6 Cdh11 -/- saline, n = 13 WT 
bleomycin, n = 11 Cdh11 -/- bleomycin.  n = 7 Bleo + isotype, n = 8 Bleo + 13C2, and n = 6 Bleo 
+ 23C6.  Values given are mean cell counts + SEM.  *P < 0.05 versus Saline; #P < 0.05 versus 
bleomycin.   
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were isolated and counted.  Results display characteristic increases in macrophages, 
eosinophils, lymphocytes and neutrophils in mice given bleomycin versus saline.  Although 
pulmonary lymphocyte numbers were reduced in Cdh11 -/- and anti-CDH11 treated mice given 
bleomycin, pulmonary inflammation was otherwise unchanged.  These results suggest that 
CDH11-dependent profibrotic effects are largely independent of pulmonary inflammation.   
  
CDH11-dependent regulation of TGF-β  
 TGF-β is a well-recognized profibrotic mediator due, in part, to its ability to induce EMT 
and the differentiation of myofibroblasts resulting in excess collagen production.  Also, TGF-β is 
elevated in bronchoalveolar lavage fluid from mice given bleomycin and patients with 
pulmonary fibrosis.  To determine CDH11-dependent effects on TGF-β, BAL fluid levels of 
soluble TGF-β were determined in Cdh11 -/- and anti-CDH11 treated mice given bleomycin.  
Results demonstrate typical increases in BAL TGF-β from WT mice given bleomycin (Figure 
4.13A,B).  In contrast, Cdh11 -/- mice and anti-CDH11 treated mice given bleomycin displayed 
markedly reduced levels of BAL TGF-β.  Further, Cdh11 -/- mice demonstrated significantly 
lower levels of TGF-β at baseline compared to WT mice given saline (Figure 4.13A).  
Localization studies demonstrate that the majority of TGF-β is produced in the alveolar 
macrophage (166, 167).  To isolate and quantify TGF-β at its source in the model, total protein 
was isolated from inflammatory cells pelleted from BAL fluid.  Findings display expected 
increases in cell pellet TGF-β isolated from mice given bleomycin, but significant decreases in 
Cdh11 -/- and anti-CDH11 treated mice given bleomycin (Figure 4.13C,D).  These results 
suggest CDH11 present on alveolar macrophages (Figure 4.1E, 4.2D) regulates the expression 
of TGF-β. 
 83 
 
 
 
Figure 4.13 - CDH11-dependent regulation of TGF-β 
BAL fluid was collected from both cohorts at day 21 after IT bleomycin.   TGF-β levels were 
quantified in (A,B) BAL supernatants and (C,D) protein lysates from BAL cell pellet utilizing a 
standard TGF-β ELISA.  n = 6 WT, n = 6 Cdh11 -/- saline, n = 13 WT bleomycin, n = 11 Cdh11  
-/-
 bleomycin.  n = 6 saline, n = 7 Bleo + isotype, n = 8 Bleo + 13C2, and n = 6 Bleo + 23C6.  
Values given are mean + SEM.  *P < 0.05 versus WT saline; #P < 0.05 versus bleomycin + 
isotype.   
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Chapter 4 - Discussion 
Differentiation of lung fibroblasts and EMT are two processes implicated in the 
formation of myofibroblasts, the cardinal cell type contributing to the pathogenesis of pulmonary 
fibrosis (8, 17, 131).  However, a complete understanding of mechanisms driving these 
processes is yet to be achieved.  The presence of CDH11 on cell types of varying origin 
contributes to a mesenchymal morphology and invasive phenotype characteristic of epithelial 
cells undergoing EMT.  Furthermore, CDH11 is upregulated during the process of 
myofibroblast differentiation (160) and in biopsies from patients exhibiting skin fibrosis (161).   
Therefore, we hypothesized that CDH11 contributes to pulmonary fibrosis.  To test this, 
expression and localization of CDH11 in human IPF samples were examined.  Further, Cdh11 -
/-
 and wild type mice given systemic CDH11 blocking antibody were exposed to intratracheal 
bleomycin and pulmonary endpoints consistent with fibrosis were examined.  Findings (Figure 
4.14) represent the first demonstration of CDH11 expression on hyperplastic AECs and 
alveolar macrophages (Figures 4.1-3), key cell types implicated in the pathogenesis of human 
IPF.  We are also first to report the CDH11-dependent regulation of EMT (Figures 4.9-11) and 
the production of TGF-β (Figure 4.13), two pivotal processes in the pathogenesis of IPF.   It 
follows that Cdh11 -/- (Figures 4.4-6) and mice given CDH11 antibody (Figures 4.7,8) showed 
marked reductions in endpoints consistent with fibrosis including the formation of 
myofibroblasts and the deposition of collagen.  Thus, agents targeting CDH11 warrant 
consideration for the treatment of patients with IPF and other fibroproliferative diseases.   
A review (163) by Moeller et. al clearly characterizes two distinct phases of the 
intratracheal bleomycin model of pulmonary fibrosis.  First an ‘inflammatory phase’, from day 
zero to day seven after bleomycin installation, characterized by massive influx of inflammatory 
cells and expression of proinflammatory cytokines and chemokines. The second is a ‘fibrotic 
phase’ characterized by profibrotic mediators such as TGF-β and production and deposition of 
extracellular matrix proteins such as fibronectin and collagen.  Studies containing agents 
administered before or during the inflammatory phase are deemed ‘preventative’ because 
observed effects are before fibrosis is established and largely dampen pulmonary inflammation.  
This review emphasizes the lack of studies containing agents administered in the second 
phase, or those that aim to treat existing pulmonary fibrosis. 
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Currently, prevention of IPF is impractical due to subclinical pathology occurring in 
the vast majority of patients.  In other words, in many patients, fibrotic foci destroy a substantial 
portion of alveolar air-spaces before gas exchange is hindered beyond the body's capacity of  
 
Figure 4.14 - Working model of cadherin 11-dependent pulmonary fibrosis 
In vivo and in vitro studies demonstrate that CDH11 present on hyperplastic epithelial cells 
contributes to the process of EMT leading to production of collagen.  Additionally, we are the 
first to demonstrate CDH11 expression on a hematopoietic cell, the alveolar macrophage.   
Data suggests that CDH11 on alveolar macrophages regulates the production of TGF-β from 
this source leading to further stimulation of collagen production through the regulation of EMT 
and differentiation of myofibroblasts.   
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compensation.  At that point, it still may be months or years before patients acknowledge that 
their notoriously non-specific symptoms of shortness of breath and fatigue have an underlying 
cause worthy of a visit to the doctor.  Furthermore, it is obvious that immunomodulatory and 
anti-inflammatory agents do not alter disease progression or improve the grim survival rates in 
these patients (168).  Finally, the side effect profile accompanying the use of these agents is 
reason enough for investigation of new therapies.  Hence, while interesting, agents targeting 
inflammation or studies otherwise designed to prevent pulmonary fibrosis in animal models 
have little utility with regard to advancing patient care for IPF.  Therefore, one aim of this study 
was to investigate the feasibility of specifically treating established pulmonary fibrosis by 
targeting CDH11. 
Mice given bleomycin and subsequently treated ten days later with CDH11 blocking 
Ab displayed substantial reductions in typical pulmonary fibrotic endpoints (Figures 4.7,8).  
Although reductions in lymphocytes were observed, this treatment effect was otherwise 
independent of any changes in inflammatory cell counts (Figure 4.12).  While this may be 
attributable to the strategic delivery of CDH11-targeted therapy after the 'inflammatory phase', 
Cdh11 -/- mice receiving bleomycin displayed virtually identical inflammatory cell counts and 
differentials.  This suggests that observed anti-fibrotic effects resulting from pharmacologic 
inhibition of CDH11 are a direct result of targeting EMT and TGF-β as opposed to affecting 
these endpoints indirectly through inflammation.  This emphasizes the promise and novelty of 
CDH11 as a therapeutic target for pulmonary fibrosis.   
CDH11 is associated with a mesenchymal phenotype in cells during development 
and in various forms of pathology including cancer and rheumatoid arthritis.  Though referred to 
as a marker of EMT (169-172), the role of CDH11 in promoting this process has not been 
investigated.  We report CDH11 expression on AECs in the bleomycin model of pulmonary 
fibrosis and patients with IPF (Figures 4.1,2).  Hyperplastic AECs are found in fibrotic regions in 
patients with IPF (154, 164, 165), commonly express epithelial and mesenchymal markers, and 
thus, are suggested to represent a transitional epithelial cell undergoing EMT.  Though its 
significance to human pathology is still under investigation, the contribution of epithelial cells to 
fibroblast and myofibroblast populations in the lung is well documented (145, 146, 173).  In vitro 
studies of epithelial cells stimulated to undergo EMT demonstrate substantial upregulations in 
CDH11 (Figure 4.9) consistent with in vivo findings in the bleomycin model (Figure 4.2) and 
patients with IPF (Figure 4.1).  Results demonstrate that CDH11 permits the process of TGF-β-
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induced EMT of epithelial cells (Figures 4.10,4.11) suggesting a mechanism of reduced fibrosis 
in mice where CDH11 is genetically and pharmacologically targeted.   
Patients with ILD, including IPF, and mice given bleomycin demonstrate CDH11 on 
alveolar macrophages (Figures 4.1-4.3), the principle source of TGF-β in clinical and 
experimental pulmonary fibrosis.  TGF-β induces differentiation of myofibroblasts and 
stimulates epithelial cells to undergo EMT.  Targeting TGF-β has demonstrated success in 
experimental pulmonary fibrosis and was recently FDA-approved for treatment of IPF.  The 
heralded critical regulatory step of (patho)biologic TGF-β activity is the activation of TGF-β 
protein through cleavage of the LAP protein fragment by various proteases (174-176).  
However, we demonstrate for the first time that CDH11 dramatically regulates the expression of 
TGF-β in bleomycin induced fibrosis from alveolar macrophages (Figure 4.13).  In the context 
of TGF-β activity in pathologic scenarios, regulation of substrate availability upstream of protein 
cleavage would influence its overall activity as evidenced by our study demonstrating paralleled 
reductions in fibrotic endpoints in vivo. These endpoints include known TGF-β-mediated 
fibroproliferative processes such as myofibroblast production and EMT.  Given the extensive 
regulation of TGF-β by CDH11, the results of this study are of value as knowledge of pathologic 
mechanisms centered about TGF-β continues to expand.   
There are likely numerous initiating stimuli driving the CDH11-dependent expression 
of TGF-β from alveolar macrophages.  However, while TGF-β promotes several factors 
important in the progression of fibrosis, CDH11-dependent EMT and a significant impact on 
TGF-β production suggests that CDH11 is important in the initiation and maintenance of the 
fibrotic phase of disease.  Given the classic cadherin function of homophilic interaction, once 
expressed on the surface of hyperplastic AECs, CDH11 may be free to interact with CDH11 on 
macrophages.  This would support a feed-forward model of perpetual TGF-β production and 
further propagation of EMT and myofibroblast formation (Figure 4.13).  Because the functions 
of CDH11 and TGF-β are closely linked via interactions of at least these two different cell types, 
targeting CDH11 and TGF-β in combination may represent a powerful approach in the 
treatment of pulmonary fibrosis.   
There is extensive potential for the influence of cadherins on profibrotic intracellular 
signaling pathways.  It is well recognized that cadherin-dependent formation of adherens 
junctions regulates the actin cytoskeleton through Rho GTPases (177).  Of note, activation of 
Rho GTPases is increased in fibroblasts of patients with IPF and promotes their migratory 
phenotype (178).  Furthermore, increased activation of Rho GTPase was detected during TGF-
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β-dependent myofibroblast differentiation in vitro (179).  These studies support the in vivo 
evidence of CDH11-dependent formation of myofibroblasts (Figures 4.5, 4.8) and suggest 
direct influence of CDH11 on fibroblast migration and myofibroblast differentiation through the 
action of Rho GTPases.  While myofibroblast formation in our study is most likely the result of 
CDH11-directed upregulations in TGF-β (Figure 4.13), other investigations indicate this may 
also be mediated by Rho activity.   Interestingly, one study found that Rho GTPase activation in 
macrophages positively regulates TGF-β translation (180).  In addition, inhibition of signaling 
downstream of Rho activity reduced experimental kidney fibrosis in association with reduced 
expression of TGF-β (181).  These studies provide insight into potential mechanisms of 
CDH11-dependent regulation of TGF-β expression and further suggest details of CDH11-
mediated fibrosis.   
Alternatively, previous studies indicate the role of the Wnt pathway in promoting 
endpoints consistent with pulmonary fibrosis such as EMT (165), lung fibroblast proliferation, 
and ECM production (182).  Other reports demonstrate increased nuclear localization of β-
catenin in type II AECs and fibroblasts of patients with IPF (165, 183, 184) indicative of 
increased Wnt signaling.  Classically, the cadherin cytoplasmic tail is bound to β-catenin 
through intermediary interaction with α-catenin.  Interestingly, a recent study demonstrates that 
cadherin-bound β-catenin is released upon adherens junction dissociation and becomes part of 
the intracellular pool available to signal within the canonical Wnt/β-catenin pathway (185).  
Epithelial cadherins, especially E cadherin, are critical in maintaining epithelial cell-to-cell 
junctions through adherens junctions.  Loss of these adherens junctions, mainly through 
downregulation of E cadherin, is a fundamental and critical step in the process of EMT.   As 
demonstrated previously (Figures 4.9-4.11), CDH11 promotes EMT in lung epithelial cells.  
Therefore, CDH11-dependent transition to mesenchymal morphology may mobilize intracellular 
β-catenin pools increasing substrate for the profibrotic Wnt intracellular signaling pathway.   
Finally, cadherins can associate with numerous tyrosine kinase receptors and 
influence their downstream intracellular signaling pathways which have been suggested to 
promote pulmonary fibrosis (186-189).  E cadherin can associate with and influence activity of 
the EGF receptor even in the absence of its ligand, EGF (190).  CDH11 (191) and N cadherin 
(192) interact with and promote the downstream signaling pathways of the FGF receptor during 
neurite outgrowth.  Finally, interaction between VE-cadherin and VEGF receptor increases the 
half life of the receptor (193).  In addition, similar to CDH11, these receptors are expressed on 
AECs and alveolar macrophages in the context of experimental and clinical pulmonary fibrosis.  
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Therefore, conceivable mechanisms of CDH11-dependent EMT and regulation of TGF-β 
involve potentiation of profibrotic signaling through tyrosine kinase receptor pathways on AECs 
and alveolar macrophages.     
While we are only in the beginning stages of understanding the mechanisms of 
CDH11-driven fibrosis, the results of this study clearly demonstrate promise to have a 
significant impact in the management of a number of conditions in addition to IPF.  The model 
of chronic, repetitive injury leading to dysregulated wound healing and collagen production has 
been applied and demonstrated in virtually every organ exhibiting fibrosis.  It follows that the 
processes of EMT and myofibroblasts differentiation play a central role in the pathogenesis of 
these conditions.   
Organ fibrosis is a substantial health problem worldwide and represents primary 
pathology or a complicating factor in a significant fraction of health-related deaths in the United 
States (2).  Cirrhosis of the liver, a fibroproliferative condition potentially arising from alcoholism 
or infectious hepatitis, is the tenth leading cause of health-related death in the United States.  
Kidney diseases of varying etiology such as diabetes (5th-leading cause of death), chronic 
nephritic and nephrotic inflammatory conditions (8th), and hypertensive renal disease (11th) 
may all exhibit renal fibrosis as an end-stage/complicating factor.  Similarly, fibrosis arises in 
the heart from a number of etiologies, but the vast majority occurs after myocardial infarct 
which is the leading cause of death in the United States.  Furthermore, organ fibrosis is a 
complicating feature of a number of existing therapeutic regiments such as chemotherapy and 
radiation in the treatment of malignancies.  We have clearly demonstrated CDH11 as a key 
regulator of EMT and myofibroblast differentiation thus underscoring the potential of CDH11-
targeted therapy to have a momentous impact in the management of human disease.   
Finally, CDH11 has an established role in promoting malignancy.  As mentioned 
previously, the role of cadherins in the process of EMT-dependent malignant transformation 
has been well-established.  Findings in this study exhibiting the role of CDH11 in promoting 
EMT will contribute to the overall understanding of this process in malignant transformation and 
metastasis.   As parallels between mechanisms of malignancy and fibrosis continue to be 
realized, results demonstrated in this thesis will aid the investigation of CDH11 as a potential 
marker or therapeutic target for cancer, the second leading cause of death in the United States. 
In summary, results of this study suggest that CDH11 on AECs and alveolar 
macrophages directly contribute to fibrosis through the regulation of EMT and TGF-β 
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production, respectively (Figure 4.14).  As continuing investigation supports the role of EMT in 
the development of organ fibrosis, this research indicates that CDH11 is a necessary endpoint 
to monitor as other players in these conditions are considered.  We have also established that 
consideration must be given to CDH11 as research continues to understand the role of TGF-β 
in the development of fibrosis and as existing TGF-β-targeted therapies are optimized.  
Understanding of detailed mechanisms regulating expression of CDH11, its ligand(s), and 
resulting downstream signaling pathways promoting organ fibrosis will be essential to further 
the development of CDH11 as a treatment option for fibroproliferative disorders. 
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Chapter 5 - Future Directions 
 With regard to the investigation of any subject, inevitably, the ability to ask pertinent 
questions exceeds the capacity to adequately address them.  Thus, the culmination of this 
dissertation leaves many unanswered questions in its wake.  Nevertheless, answers to these 
questions are important to further the appreciation of the roles of OPN and CDH11 in human 
pathology.   
Characterize the contribution of αvβ3 integrin to the Ada -/- pulmonary phenotype 
 This dissertation demonstrates that OPN contributes to pathologic air-space 
enlargement in a model of adenosine-mediated lung injury.  Results also suggested that 
features of this phenotype were mediated by OPN-dependent recruitment of neutrophils 
through interactions with CD44 and αvβ3.  An attempt to ascertain the contribution of CD44 to 
the Ada -/- phenotype produced inconclusive results.  This could reflect the need for 
optimization of the experimental design, or might suggest that OPN-CD44 interaction does not 
significantly contribute to the overall Ada -/- phenotype.  Because OPN-αvβ3 interactions in 
different scenarios contribute to an array of human pathology, future studies should investigate 
the role of αvβ3 in the Ada -/- pulmonary phenotype utilizing similar neutralization strategies and 
pulmonary endpoints outlined in chapter 3.   
OPN-dependent regulation of adhesion molecules 
 Results in this thesis demonstrate that OPN interactions with its two putative receptors 
promote the recruitment of neutrophils, in vivo.  These results were found to be independent of 
changes in lung proinflammatory cytokines or granulopoiesis associated with the genetic 
removal of Opn.  While this suggests a direct OPN interaction with these receptors on the 
surface of neutrophils, additional mechanisms need to be investigated and/or ruled out.  
Elevated adenosine levels in the Ada -/- model are associated with increased expression of 
adhesion molecules, such as P-selectin, E-selectin, VCAM and ICAM, responsible for 
promoting the recruitment of neutrophils from the bloodstream to sites of tissue injury.  Thus, 
future experiments need to address the contribution of OPN to adenosine-dependent 
upregulations in adhesion molecules promoting neutrophil extravasation into injured lung 
tissue.   
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Role of OPN in alternative models of emphysema/COPD 
 Despite the demonstrations that OPN contributes to the pathogenesis of adenosine-
mediated alveolar air-space enlargement and OPN expression is increased in human tissue 
obtained from patients with COPD, there are indications that the Ada -/- model does not fully 
represent the pathology seen in COPD.  Two alternative, perhaps more well-accepted, models 
of emphysema include chronic cigarette smoke exposure and repeated administration of 
cigarette smoke extract (CSE) through various routes.  Nevertheless, these models exhibit 
inflammation and alveolar air-space enlargement similar to the Ada -/- model.  Therefore, to 
solidify the contribution of OPN to experimental emphysema, future studies may include the 
examination of standard endpoints consistent with emphysema in Opn -/- mice exposed to 
cigarette smoke or CSE. 
Localization of β catenin 
 Findings in this dissertation demonstrate a pivotal role of CDH11 in promoting the 
process of EMT thus promoting pulmonary fibrosis.  Cadherins involved in cell-to-cell adhesion 
at so-called adherens junctions bind intracellular proteins including β catenin that, under certain 
conditions, are involved in profibrotic intracellular signaling pathways.  Upon adherens junction 
dissociation, as in the case of EMT, there exists evidence that cadherin-bound β catenin is 
released and is available to signal within the Wnt intracellular signaling pathway which many 
studies indicate promotes pulmonary fibrosis.  However, CDH11-dependent localization of β 
catenin in the context of pulmonary fibrosis is not yet known.   Presumably, CDH11 permitting 
the process of EMT in airway epithelial cells would lead to dissociation of adherens junctions 
thus releasing cadherin bound β catenin.  Preliminary studies demonstrate β catenin localizes 
in cytoplasmic/perinuclear regions away from cell membrane bound CDH11 on alveolar 
macrophages isolated from patients with ILD (Figure 5.1).  Subsequent experiments should 
involve immunolocalization of β catenin and CDH11 in AECs undergoing EMT.  These studies 
should be performed in vitro, where CDH11 expression can be directly manipulated, and in vivo 
to confirm this process occurs in the overall setting of pulmonary fibrosis.  If CDH11 promotes 
dissociation of adherens junctions in either cell type, results displaying nuclear, as opposed to 
cytoplasmic cell surface, localization of β catenin would suggest the CDH11-dependent release 
of β catenin permitting its signaling within profibrotic intracellular pathways.   
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Figure 5.1 - Dual CDH11 β-catenin immunofluorescence on ILD macrophages 
Alveolar macrophages isolated from a patient with ILD secondary to scleroderma expresses 
CDH11 (red) on the cell surface and β-catenin (green) in cytoplasmic/perinuclear regions (white 
arrows).    
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CDH11-dependent expression of TGF-β in alveolar macrophages  
 TGF-β is well-established as the quintessential profibrotic mediator.  Findings in this 
thesis exhibit that CDH11-mediated development of pulmonary fibrosis may be a consequence 
of the regulation of TGF-β expression from alveolar macrophages.  While we have confirmed 
that changes in TGF-β expression are not due to CDH11-mediated changes in macrophage 
numbers, conceivable scenarios exist independent of CDH11 on alveolar macrophages directly 
influencing the expression of TGF-β.  Therefore, future experiments should involve the 
examination of TGF-β production in response to appropriate stimulus in the presence and 
absence of CDH11 on alveolar macrophages.  This would involve the collection of primary 
alveolar macrophages from wild type and Cdh11 -/- mice or the use of previously described 
Cdh11 -/- knockdown techniques, in vitro.  Known inducers of TGF-β production from alveolar 
macrophages in vitro include phosphatidyl serine recognition structures and bleomycin.  
Discrepancies in induced in vitro TGF-β production from alveolar macrophages with and 
without CDH11 would definitively indicate direct regulation of TGF-β expression by CDH11.   
CDH11-dependent clearance of ‘debris’ by alveolar macrophages 
 Preliminary data indicates that Cdh11 -/- mice, in parallel with a reduction in endpoints 
consistent with pulmonary fibrosis in response to bleomycin, exhibit an atypical morphology in 
alveolar macrophages isolated from BAL (Figure 5.2A).  Unpublished data from Dr. Blackburn’s 
lab reports the appearance of alveolar macrophages with basophilic inclusions in association 
with the resolution of fibrosis.  We postulate that these inclusions, present almost exclusively in 
Cdh11 -/- macrophages (Figure 5.2B), represent the phagocytosis of apoptotic cells or ECM 
proteins.  Initial steps, such as collagen Ab or TUNEL staining, should be taken in future 
studies to determine the nature of these inclusions.  Enhanced survival or decreased apoptosis 
of myofibroblasts is reported in the scientific literature as a mechanism of dysregulated wound 
healing leading to fibrosis.  Future work should involve characterization of apoptosis within or 
adjacent to regions of fibrotic foci in existing tissue sections of mice given bleomycin where 
CDH11 is genetically and pharmacologically targeted.  Subsequent studies should examine the 
role of CDH11 and apoptosis in fibroblasts stimulated to differentiate into myofibroblasts, in 
vitro.  Alternatively, enhanced clearance of extracellular matrix in the absence of CDH11 may 
be explained by normalization of protease/antiprotease imbalances characteristic of pulmonary 
fibrosis.  Investigation and quantification of proteases, such as the matrixmetalloproteases, and  
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Figure 5.2 - ‘Inclusion’ cells in Cdh11 -/- alveolar macrophages 
(A) Diff-Quick-stained BAL cytospins isolated from WT and Cdh11 -/- mouse lungs treated with 
bleomycin.  Arrows denote basophilic inclusions present within alveolar macrophages of Cdh11 
-/-
 mice.  Scale bars = 50 µm.  (B) Quantification of inclusion cells present within 7 low 
magnification images per sample.  Inclusion cell numbers were normalized to total cell number 
present in BAL from each sample.  n = 9 (WT) and n = 7 (Cdh11 -/-).  *P < 0.05 versus WT.   
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their corresponding inhibitors, TIMPs, may provide insight into the enhanced clearance of 
extracellular matrix and improved pathology exhibited by Cdh11 -/- mice. 
Further characterization of pulmonary endpoints in the bleomycin and Ada -/- model 
 Clinical endpoints typically monitored and associated with pulmonary fibrosis and 
COPD are arterial oxygen saturation (SpO2) and pulmonary function tests (PFTs).  PFTs 
identify a restrictive pattern in pulmonary fibrosis and an obstructive pattern in COPD.  
Recently, our lab has encountered technology enabling the measurement of these endpoints.  
Future studies in the both models should include full characterization of OPN and CDH11-
dependent changes in lung volumes and compliance with a FlexiVent system and SpO2 with 
the MouseOx detection system. 
Overlap between CDH11 and OPN? 
 Initially, there is reason to believe that CDH11 and OPN have overlapping pathologic 
mechanisms.  Both have been studied in cancer and organ fibrosis.  However, reports in the 
cancer literature suggest that CDH11 is involved with the acquisition of a mesenchymal 
phenotype, whereas OPN promotes the migration of tumor cells directly through interactions 
with cell surface receptors and indirectly via activation of extracellular matrix proteases and 
promoting angiogenesis.  This thesis and the existing literature display that the roles of these 
individual proteins show striking similarity between mechanisms promoting malignant 
transformation and pulmonary fibrosis.  However, despite our reports that CDH11 promotes 
features of pulmonary fibrosis similar to previous in vivo studies done in Opn -/- mice (97, 98), 
the mechanisms of fibrosis appear to occur in parallel rather than in overlapping manner.   
 In contrast to Cdh11 -/- mice, Opn -/- knockout mice have reduced pulmonary 
inflammation in the Ada -/- model (194) and the bleomycin models of pulmonary fibrosis (97, 
98).  Furthermore, studies demonstrate that OPN induces fibroblast migration and invasion 
through interactions with the putative OPN receptors (82, 97).  In contrast, we have suggested 
that any CDH11-mediated cell migration would be the direct result of EMT.  In addition, these 
processes are likely secondary to CDH11-dependent upregulations in TGF-β, interactions with 
other cadherins, or influence within tyrosine kinase receptor signaling pathways.  Finally, there 
is discrepancy with regard to the influence of OPN on the levels of TGF-β in vivo (97, 194).  In 
contrast, we report that CDH11 has a considerable affect on the expression of TGF-β in the 
bleomycin model.   
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 However, one area where cadherin and OPN pathways may intersect is at the post-
translational level.  Findings in this dissertation of OPN mediated increases in MMP protein 
levels are consistent with OPN-mediated increases in MMP activity in the cancer literature and 
studies of Opn -/- mice in the bleomycin model.  It has been reported recently that MMPs 
facilitate the disruption of E cadherin at adherens junctions promoting the process EMT (152).  
While we have shown CDH11 directly promotes EMT in lung epithelial cells in vitro, it is 
conceivable that this process may be aided by OPN-mediated increases in MMP activity in 
vivo.  If further study of CDH11-directed fibrosis displays dependency or facilitation by MMP 
activity, the role of OPN in CDH11-dependent EMT in vivo may warrant investigation. 
Conclusion 
This thesis demonstrates novel roles for OPN and CDH11 in the development of 
chronic lung diseases.  This thesis exhibits the role of OPN-driven neutrophilia, increases in 
proteases, and angiogenesis in association with OPN-dependent alveolar air-space 
enlargement consistent with COPD in vivo.  Further, in the context of CDH11-dependent 
pulmonary fibrosis, we demonstrate that CDH11 regulates epithelial to mesenchymal transition 
and production of TGF-β from macrophages.  These processes all have demonstrated roles in 
normal wound healing.  These findings support the overriding hypothesis that mechanisms of 
chronic lung disease are a result of over-activity of normal wound healing processes.  It follows 
that an overall understanding of factors shifting physiology from 'normal' to pathologic wound 
healing will be necessary as we continue to gain knowledge of the mechanisms of all diseases 
that are chronic in nature.   
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